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ABSTRACT 
Gamma-aminobutyric acid (GABA) is the predominant inhibitory 
neurotransmitter in the central nervous system. Its activity at the synapse is 
terminated by re-uptake into nerve terminals and astrocytes, through membrane 
located specific GABA transporters (GATs), which therefore shape GABAergic 
transmission. There are three main high affinity subtypes of GATs, GAT-1, GAT-
2 and GAT-3, and a low affinity one, the betaine transporter. GAT-1 is the 
predominant GABA transporter in the brain and is expressed in neurons and 
astrocytes.  
Several factors can regulate the continuous traffic of GATs to and from the 
neuronal plasma membrane. For instance surface expression of GAT-1 in cultured 
neurons and isolated nerve terminals is decreased by protein kinase C (PKC)-
dependent phosphorylation. In contrast, surface expression of GAT-1 in neurons 
is enhanced by brain derived neurotrophic factor (BDNF)-mediated tyrosine 
kinase-dependent phosphorylation. Though reuptake of GABA might occur at 
different places of the neuronal membrane, its reuptake by the nerve terminal is 
the process that allows quick refilling of the released stores. On the other hand, 
uptake by astrocytes contributes to a fast removal of GABA from the synapse and 
delays its delivery to the neuronal release stores. To understand how GABAergic 
transmission can be shaped, it is therefore important to know how a single 
modulator can affect both processes of GABA removal from synapse.  
Thus, in the work presented on this thesis I evaluated the influence of BDNF upon 
GAT-1 transporters on presynaptic nerve terminals and cortical primary astrocyte 
culture. 
BDNF decreased GAT-1 mediated GABA uptake by isolated hippocampal rat 
nerve terminals (synaptosomes), an effect that occurred within 1 min of 
 xxiii 
incubation with BDNF through activation of TrkB receptor. In contrast with what 
has been observed for other synaptic actions of BDNF, the inhibition of GABA 
transport by BDNF does not require tonic activation of adenosine A2A receptors, 
nevertheless is facilitated by activation of A2A receptors.  
On the other hand, BDNF enhances GAT-1 mediated GABA transport in cultured 
astrocytes, an effect mostly due to an increase in Vmax kinetic constant. This effect 
involves the truncated form of TrkB receptors (TrkB-t) coupled to a non-classic 
PLC-/PKC-δ and Erk/MAP kinase pathway and requires active adenosine A2A 
receptors. To elucidate the trafficking of GAT-1 when astrocytes were treated 
with BDNF, a functional mutant of the rat GAT-1 was generated in which 
hemagglutinin epitope (HA) was incorporated into the second extracellular loop. 
By ELISA experiments, performed with astrocytes expressing HA-rGAT-1 
transporter, it was possible to observe an exocytosis of HA-GAT-1 to plasma 
membrane when cells were treated with BDNF. In addition, cell surface 
biotinylation experiments, performed with astrocytes overexpressing the wild type 
rat GAT-1 (rGAT-1), also demonstrate an increase of GAT-1 transporter at 
plasma membrane when astrocytes were treated with BDNF. Results from 
experiments using selective inhibitors of endocytosis or selective inhibitors of 
recycling of molecules back to the plasma membrane allowed concluding that 
BDNF enhances GAT-1 expression at surface astrocytic membrane by slowing 
down exocytosis. 
A new role for BDNF is proposed whereby the effect of BDNF on GAT-1 
transporter differs between pre-synaptic nerve terminals and astrocytes, 
suggesting that this neurotrophin operates in a much localized way, so that it may 
retard GABA uptake by the nerve terminal, enhancing synaptic actions of GABA, 
and accelerate its reuptake at extracellular neuronal areas allowing replenishment 
of neuronal pools of GABA. The results suggest that BDNF plays an active role 
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in the regulation of GABAergic synaptic signalling, contributing to information 
processing. 
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RESUMO 
O ácido -aminobutírico (GABA) é o principal neurotransmissor inibitório do 
sistema nervoso central. A rápida remoção do GABA presente na fenda sináptica, 
por transportadores de alta afinidade para o GABA, que se localizam quer a nível 
do terminal pré-sináptico dos neurónios, quer a nível das células da glia, 
nomeadamenrte dos astrócitos (Gether et al., 2006), é essencial para uma 
sinalização eficaz mediada por este neurotransmissor. Até ao momento quatro 
transportadores foram identificados para o GABA, três destes de alta afinidade, 
denominados de GAT-1, GAT-2 and GAT-3 e um quarto, de baixa afinidade, 
denominado betaine transporter. O transportador GAT-1 é o transportador de 
GABA predominante no sistema nervoso central e encontra-se expresso 
preferencialmente em neurónios, sendo, no entanto, também expresso em 
astrócitos. Relativamente ao transportador GAT-3, sabe-se que este é 
maioritariamente expresso em astrócitos, onde tem um predomínio de transporte 
de GABA relativamente ao transportador GAT-1. Assim a recaptação de GABA 
pode ocorrer em diferentes localizações celulares. Quando ocorre para o terminal 
nervoso pre-sináptico, tem como consequência uma rápida reposição do nível de 
GABA nas vesículas sinápticas. A ocorrência para os astrócitos contribui para 
uma remoção mais rápida do GABA da fenda sináptica, diminuindo assim a 
velocidade de reposição de GABA nas vesículas sinápticas. Para se entender 
como é que a transmissão GABAérgica é regulada, torna-se pois extremamente 
relevante compreeender como pode apenas uma molécula modular os dois locais 
onde ocorre transporte de GABA, nomeadamente o pré-sináptico e o astrocítico. 
Salienta-se também a importância dos transportadores para o controlo da 
excitabilidade e o seu eventual envolvimento em situação patológica, 
nomeadamente em doentes com epilepsia do lobo temporal que apresentam uma 
aumento da expressão dos transportadores de GABA nos astrócitos.  
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Os transportadores de GABA são regulados de diversos modos, estando 
envolvidos diferentes factores e várias cascatas de transdução de sinal. Esta 
modulação pode ocorrer de dois modos distintos: por alteração do Km ou da Vmax 
do transportador. A regulação do tráfego dos transportadores de GABA de, e para 
a membrana plasmática neuronal, pode ocorrer por variações da velocidade de 
endocitose e exocitose e/ou por alteração da quantidade de transportadores 
disponíveis neste processo de tráfego contínuo.  
Uma molécula já identificada como reguladora do transportador GAT-1 é o Brain 
derived neurotrophic factor (BDNF). O BDNF é um factor neurotrófico com 
importantes funções na diferenciação, maturação e sobrevivência neuronal, 
levando a modificações estruturais e moleculares a longo-prazo que são cruciais 
para o desenvolvimento, mas também para a função e plasticidade sináptica no 
indivíduo adulto (Vicario-Abejon et al., 2002). O BDNF exerce a sua acção 
através da activação de receptores tirosina cinase B (TrkB), que se apresentam em 
diferentes isoformas: uma isoforma “completa” (TrkB-fl) que apresenta domínios 
tirosina cinase e uma isoforma truncada (TrkB-t) que não apresenta estes 
domínios. O BDNF favorece a recaptação de GABA devido a um aumento da 
expressão de GAT-1 a nível da membrana plasmática em culturas primárias de 
neurónios, não se sabendo até ao início deste trabalho qual a função do BDNF no 
controlo da actividade do GAT-1 local a nível de terminais nervosos.  
Os astrócitos são a maior classe de células da glia encontrada no cérebro dos 
mamíferos e têm um papel extremamente relevante na transmissão sináptica, 
contribuindo para o processamento de informação a nível sináptico ao controlar 
quer a composição do meio extracelular, quer a quantidade de neurotransmissores 
presentes na fenda sináptica. Os astrócitos são assim células fundamentais a nível 
da comunicação existente entre astrócitos ou entre astrócitos-neurónios. No que 
diz respeito à regulação dos níveis extracelulares de GABA, estas células têm um 
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papel muito importante uma vez que expressam transportadores específicos de 
GABA, que permitem, como foi anteriormente referido, o controlo dos níveis 
deste neurotransmissor na fenda sináptica. Todavia, pouco tem sido descrito em 
relação à regulação dos transportadores de GABA nos astrócitos. 
O trabalho que aqui se apresenta teve como objectivo estudar o efeito do BDNF 
sobre o transportador de GABA, em terminais nervosos pré-sinápticos e em 
astrócitos, bem como estudar os mecanismos subjacentes ao efeito do BDNF. Foi 
também abordado o possível envolvimento dos receptores A2A da adenosina, uma 
vez que a interacção entre o receptor do BDNF, TrkB e o receptor de adenosina 
A2A, tem sido descrita em vários sistemas biológicos.  
Verificou-se que em terminais nervosos pré-sinápticos o BDNF tem uma acção 
inibitória sobre o transportador exclusivo de GABA (GAT-1) nesta estrutura, 
levando a uma diminuição da recaptação de GABA através deste transportador. 
Este efeito depende da concentração de BDNF e ocorre num intervalo de tempo 
extremamente curto (1 minuto). O efeito do BDNF no transportador GAT-1 
ocorre através da activação do receptor TrkB e, contrariamente a outros efeitos 
mediados pela activação deste receptor, não requer a activação tónica dos 
receptores A2A da adenosina.  
Em culturas primárias de astrócitos o BDNF aumentou a recaptação de GABA 
mediada pelo transportador GAT-1, não tendo qualquer efeito no transportador 
GAT-3, também presente nos astrócitos. Este efeito ocorre devido a um aumento 
da velocidade máxima do transportador. O efeito do BDNF envolve a forma 
truncada do receptor TrkB, estando esta acoplada a uma via não clássica da PLC-
γ/PKC-δ e da Erk/MAP cinases. O efeito descrito requer que os receptores A2A da 
adenosina estejam activos, sendo que os níveis endógenos de adenosina 
extracelular são suficientes para desencadear o efeito do BDNF. 
  xxviii 
Uma vez que um aumento do Vmax se correlaciona com um aumento do número de 
transportadores na membrana plasmática, procedeu-se seguidamente à avaliação 
de um possível aumento da expressão do transportador GAT-1 quando as células 
eram tratadas com BDNF. Para avaliar se o efeito do BDNF se correlacionava 
com o tráfego de GAT-1 de, e para a membrana celular, foi gerado um mutante 
funcional do transportador GAT-1 de rato (rGAT-1), no qual foi introduzido o 
epítopo hemaglutinina (HA) no segundo loop extracelular do transportador, 
procedendo-se à infecção dos astrócitos com o referido mutante. Após o 
tratamento das células com BDNF observou-se um aumento da expressão de HA-
rGAT-1 na membrana plasmática. Também através de experiências de 
biotinilação, realizadas com astrócitos que sobreexpressavam rGAT-1, se pôde 
concluir que o BDNF aumenta a expressão de rGAT-1 na membrana plasmática. 
Estudos onde se usou um inibidor da endocitose (dynasore) ou um inibidor da 
reciclagem de moléculas internalizadas de volta para a membrana plasmática 
(monensin), permitiram concluir que o efeito do BDNF envolve inibição da 
internalização de GAT-1 nos astrócitos, tendo esta acção consequências na 
expressão do GAT-1 e na velocidade de transporte de GABA.  
Os resultados apresentados nesta tese mostram que o BDNF exerce a sua acção de 
um modo muito localizado, levando a uma diminuição da recaptação de GABA 
no terminal nervoso que favorece eventualmente as suas acções sinápticas, e a 
uma aceleração da recaptação de GABA em regiões extra-sinápticas, que 
contribui para uma redução da acção tónica deste neurotransmissor. Em última 
instância, este efeito do BDNF deverá determinar uma diminuição da velocidade 
de reposição de GABA nas vesículas sinápticas, conduzindo desta forma a um 
aumento da excitabilidade neuronal. 
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1. INTRODUCTION 
The complex architecture of adult brain rises from integration of genetic 
information, cellular interactions and eventually interactions between developing 
brain and the outside world. Nevertheless, the adult brain is able to keep part of 
these interactions, since it is continuously changing (neuronal plasticity), allowing 
learning, establishing new memories and even responding after an injury. The 
brain is constituted by a large number of different types of neurons, as well as 
several types of non neuronal cells, that form complex neuronal circuits. Although 
these circuits have the inherent complexity associated with biological systems, 
they can be simplified and, as a consequence, the different functional units can be 
individualized. The balance between different circuits is highly relevant for the 
correct function of brain; an example is the balance between excitatory 
(glutamatergic system) and inhibitory (GABAergic systems) circuits.  
1.1. GABA and the GABAergic system  
Gamma-aminobutyric acid (GABA) is the predominant inhibitory 
neurotransmitter in the adult brain, being discovered by three different groups in 
1950 (Awapara et al., 1950; Roberts and Frankel, 1950; Udenfriend, 1950).  
GABA biosynthesis in neurons mainly involves decarboxylation of glutamate  
yielding GABA and CO2 via the enzyme glutamate decarboxylase (GAD) 
(Roberts and Kuriyama, 1968). The glutamate can be obtain by neurons from two 
different sources, namely from glutamine that comes from tricarboxilic acid 
(TCA) cycle in glia cells and from glutamine obtain in nerve terminals (Figure 
1.1.1).  There are two isoforms of GAD, namely GAD65 and GAD67, being 
GAD67 found ubiquitously in GABAergic neurons, whereas GAD65 is 
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preferentially located in the nerve terminals. Based on these findings it has been 
suggested that GAD65 is specialized to readily synthesize GABA under short-
term demand (Martin and Rimvall, 1993). The synthesized GABA is loaded into 
synaptic vesicle through vesicular GABA transporter (VGAT) (McIntire et al., 
1997) and the complex formed by VGAT with GAD65 appears to be the 
necessary for efficient GABA synthesis and packaging into synaptic vesicles (Jin 
et al., 2003). 
In the nerve terminals GABA can be released to the synaptic cleft mainly by two 
different pathways; i.e., via a Ca2+ dependent vesicular release or a Ca2+ 
independent release through transporter reversal (Belhage et al., 1993; Kirmse and 
Kirischuk, 2006; Wu et al., 2007; Ade et al., 2008). However, other less 
characterized mechanisms might also contribute, namely non-transporter-
mediated Ca2+- and SNARE-independent release (Demarque et al., 2002), 
transmitter leakage that ocours through damaged plasma membrane (Phillis et al., 
1996), release via P2X7 receptor-activated unidentified channels (Wang et al., 
2002; Duan and Neary, 2006). Upon release to the synaptic cleft GABA interacts 
with GABA receptors located pre and postsynaptically. Presynaptic metabotropic 
GABA receptors (GABAB) mediate a negative feedback mechanism on GABA 
release whereas, postsynaptic GABA receptors, that can be both metabotropic 
(GABAB) and ionotropic (GABAA), mediate usually hyperpolarization of the cell 
(Watanabe et al., 2002).  
After dissociation from the receptor complex, GABA is transported back into the 
presynaptic nerve terminal or into surrounding astrocytes via a high affinity 
GABA transport system thereby terminating GABA’s inhibitory action (Iversen 
and Neal, 1968) and keeping the extracellular GABA concentrations under 
physiological levels. The GABA taken up by neurons can be directly loaded into 
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synaptic vesicle, while the GABA taken up by astrocytes is first catabolised to the 
TCA cycle intermediate succianate via the concerted action of GABA 
transaminase (GABA-T) and succinate semialdehyde dehydrogenase (SSADH), 
and next succianate originates -ketoglutarate via TCA cycle that will be 
funnelled out of TCA cycle and converted into glutamate by the enzyme 
glutamate dehydrogenase (Figure 1.1.1B). This TCA by-pass reaction is known as 
GABA shunt. The glutamate is converted to glutamine by glutamine synthetase 
(GS), which is afterward transported to neurons where it is converted into 
glutamate by phosphate-activated glutaminase (PAG) (Bak et al., 2006). GABA-T 
is located both on neurons and astrocytes presenting a highest activity in 
astrocytes (Madsen et al., 2008), indicating that GABA transport to neurons or to 
astrocytes have different functional consequences. Indeed it has been estimated 
that neuronal GABA transport system is three- to six-fold more efficient than the 
astrocytic GABA transport mechanisms (Hertz & Schousboe, 1987) which is 
correlated with the existence of different GABA transporters and with the 
differential expression and density of this transporter in neurons and astrocytes. 
Demonstration of a physiological role for GABA transporters comes from 
experiments involving specific GABA uptake inhibitors; these inhibitors 
prolonged the decay phase of the “fast” GABAA receptor-mediated post-synaptic 
potentials (Isaacson et al., 1993) and increase both the decay phase and the 
magnitude of responses mediated by G-protein coupled GABAB receptors 
(Dingledine and Korn, 1985; Solis and Nicoll, 1992; Isaacson et al., 1993; 
Bernstein and Quick, 1999). 
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Figure 1.1.1. Schematic representation of GABA metabolism and uptake. In GABAergic 
synapse (A), after an appropriate stimulus GABA is released from the presynaptic terminal 
activating specific GABA receptors. GABA mediated effects are finished by the uptake of GABA 
through specific GABA transporters into both the surrounding astrocytes and the pre-synaptic 
terminal. In the astrocytes, GABA is metabolized to glutamine and glutamine return to the neurons. 
In neurons the enzyme glutamic acid decarboxylase (GAD) forms GABA from glutamate, being this 
glutamate obtain from two different sources: glutamine from TCA cycle in glia cells and glutamine 
in nerve terminals. The GABA shunt is shown in red (B). GAD is the entry point for glutamate into 
the GABA shunt with succinate as end product. GABA transaminase (GABA-T) is a mitochondrial 
enzyme which converts GABA into glutamate by reaction with -ketoglutarate (-KG). (Adapted 
from Bak et al., 2006; Li et al., 2008 with small modifications). 
 
1.1.1. GABA receptors and phasic/tonic inhibition 
There are two distinct types of GABA receptors: the ionotropic GABAA 
(widespread in CNS) and GABAC (mostly found in retina) receptors and the 
metabotropic GABAB receptors. For ionotropic receptors, the ligand binding is 
followed by a conformational change in the channel protein that allows a net 
A B 
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inward flow or outward flow of ions through the membrane-spanning pore of the 
channel, depending on the electrochemical gradient of the particular permeant ion 
(Figure 1.1.2).   
GABAA receptors are pentameric and consist of several subunits (e.g. , , , , ε, 
θ, pi and ρ). To date nineteen subunits have been cloned (six  subunits, three  
subunits, three  subunits, one  subunit, one ε subunit, one θ subunit, one pi 
subunit and three ρ subunits) from the mammalian CNS, with further variation 
resulting from alternative splicing (Farrant and Nusser, 2005). A great variety of 
GABAA receptors with distinct pharmacology could be assembled by combining 
these subunits. The most common combination is triplet 1/2/2, which is 
detected in various cell types in the CNS (McKernan and Whiting, 1996). These 
receptors encompass the chloride channels and can be specifically blocked by 
bicuculline. The GABAA receptor has modulatory binding sites for 
benzodiazepines, barbiturates, ethanol and neurosteroids (Macdonald and Olsen, 
1994).  
GABAB receptors consist of a single peptide that is coupled to G-proteins through 
second messenger pathways, which change the activity of post-synaptic K+ 
channels and/or currents mediated by pre- and post-synaptic voltage-dependent 
Ca2+ channels (Marshall et al., 1999). Until now two subtypes of the receptor have 
been identified, the GABABR-1 and GABABR-2, existing two isoforms of the 
GABABR-1 (R1a and R1b) (Kaupmann et al., 1998; Pierce et al., 2002).  This 
receptor is an obligate heterodimer that is only functional when both the 
GABABR-1 and GABABR-2 are co-expressed in the same cell. When the 
GABABR-1 is expressed alone, it is trapped in vesicles within the cell, whereas 
the GABABR-2 alone is expressed on the cell surface, but cannot bind GABA or 
activate G proteins. When both receptor subunits are expressed in the same cell, 
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the receptors interact through coiled-coil domains in their carboxyl tails. They are 
then expressed on the cell surface, bind GABA and activate G proteins.  The 
GABAB receptor is activated by baclofen and antagonized by saclofen and 
phaclofen, but is insensitive to bicuculline. 
A third GABA receptor, GABAC receptor, which is pharmacologically and 
structurally distinct from GABAA and GABAB receptors, has been identified and 
occurs predominantly in the vertebrate retina (Feigenspan et al., 1993; Qian and 
Dowling, 1993; Bormann and Feigenspan, 1995; Lukasiewicz and Shields, 1998; 
Bormann, 2000). GABAC receptors are Cl- pores, which can be blocked by 
picrotoxin, a non-selective chloride channel blocker, but they are insensitive to 
bicuculline and baclofen. Structually, GABAC receptors are exclusively composed 
of a single or multiple -subunits. These subunits are heterologously expressed 
and form homoligomeric channels with the characteristic pharmacology of 
GABAC receptors (Bormann, 2000). In addition to the differences in 
pharamacology and structure, several lines of evidence indicate that GABAA and 
GABAC receptor-mediated responses have different kinetics (Bormann and 
Feigenspan, 1995; Djamgoz et al., 1995; Lukasiewicz, 1996; Han et al., 2000). 
Moreover, the GABAC receptor is more sensitive to GABA than the GABAA 
receptor. The GABA concentration, producing half-maximal response (EC50), is 
1–5 M for GABAC receptors, whereas the EC50 is 10–100 M for GABAA 
receptors (Polenzani et al., 1991; Qian and Dowling, 1993; Feigenspan and 
Bormann, 1994; Qian and Dowling, 1994; Han et al., 1997).  
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Figure 1.1.2. Subunit composition and assembly of GABA receptors. GABAA and GABAC 
receptors are closely related pentameric receptors that carry chloride; however, whereas GABAA 
receptors are composed of combinations of several subunit types, GABAC receptors are composed 
of only single or multiple ρ-subunits. GABAB receptors are metabotropic receptors that exist as R1a, 
R1b and R2 isoforms, and are associated with G proteins. Native GABAB receptors are dimmers 
composed of one R1 subunit and the R2 subunit (Adapted from Owens and Kriegstein, 2002). 
 
Two different types of GABAergic inhibition can be activated by GABA 
receptors, the phasic and tonic inhibition. Phasic inhibition, which regulates point-
to-point interneuronal communication, is related with GABAA receptors facing 
pre-synaptic release sites and is activated by a high concentration of GABA 
released by synaptic vesicle exocytosis; and tonic inhibition, which regulates 
membrane potential and network excitability (Semyanov et al. 2004; Farrant and 
Nusser 2005; Mody, 2005), is related with the exposure of extrasynaptic distant 
GABAA receptors to a persistently low concentration of “ambient” GABA 
(Lindquist and Birnir 2006). The peak concentration of synaptic GABA (1.5 – 3 
mM) differs considerably from the “ambient” GABA concentration found in 
extrasynaptic regions (0.2 – 0.8 µM) (Lerma et al., 1986; Mozrzymas et al., 
2003). Interesting the concentration of GABA in extrasynaptic regions is 
sufficient to activate extrasynaptic GABAA receptors (Figure 1.1.3) but not 
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GABAA receptors within the synaptic cleft, since the subunit composition of 
synaptic and extrasynaptic GABAA receptors differs, so that extrasynaptic 
receptors have much higher sensitivity to GABA and much slower desensitisation 
kinetics. 
The extrasynaptic GABA concentration is maintained by GABA that escapes 
from the synaptic cleft (GABA spillover) or that is released via non-vesicular 
mechanism by neurons and glia (Isaacson et al., 1993; Mitchell and Silver, 2000; 
Scanziani, 2000; Volknandt, 2002; Ruiz et al., 2003; Semyanov et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1.1.3. Sources and targets of extrasynaptic GABA. Extracellular GABA concentration is 
regulated by release, diffusion and uptake mechanisms. GABA can escape from synaptic cleft 
(GABA spillover) and can be released via non-vesicular mechanism by neurons and glia. Once 
released, GABA can reach target receptors on presynaptic terminals, axon and somatodendritic 
compartments (Adapted from Semyanov et al., 2004). 
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1.2. GABA transporters 
The concept that after release the neurotransmitter is inactivated by uptake into 
the nerve terminal from which it had been released or into adjacent cells is less 
than 50 years old. In 1958 was first described that GABA in the incubating 
medium could accumulate into slices of cerebral cortex (Elliott and Van Gelder, 
1958); however the discovery of a high affinity transport system for GABA in 
neurons and astrocytes was only achieved 10 years later (Iversen and Neal, 1968; 
Iversen and Kelly, 1975). Until now, four GABA transporters have been 
characterized and cloned: there are three high affinity subtypes of GABA 
transporter, GAT-1-3, and a low affinity one, betaine-GABA transporter 1 (BGT-
1). 
Radian and collaborators (1986) isolated for the first time a Na+ and Cl- dependent 
GABA transporter from rat. Afterwards this transporter was cloned and 
designated GAT-1 transporter (Guastella et al., 1990). This revealed a 599 amino 
acid content and a Km of 7µM for GABA (Guastella et al., 1990). The GAT-1 
transporter was later on cloned from human (Nelson et al., 1990). 
Three other GABA transporters were identified. Two rat GABA transporters 
designated rGAT-2 and rGAT-3 with a Km of 8 and 12 µM for GABA, 
respectively, and an amino acid sequence of 602 and 627, respectively, have also 
been cloned (Borden et al., 1992). Both human GAT-2 and GAT-3 have been 
identified and cloned (Borden et al., 1994b; Christiansen et al., 2007). Finally a 
transport protein capable of transporting both GABA and the osmolyte betaine 
with an apparent Km of 93 and 398 mM, respectively, was isolated from rat kidney 
and named betaine-GABA transporter 1 (BGT-1) (Yamauchi et al., 1992). It 
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encodes a 614 amino acid protein also with a dependence on Na+ and Cl- for 
transport. The human BGT-1 has also been cloned (Borden et al., 1995). 
Four mouse GABA transporters displaying a Na+ and Cl- dependence for transport 
have been also cloned and characterized pharmacologically. The mouse GABA 
transporters are termed GAT1, GAT2, GAT3, and GAT4 (without hyphen) and 
are composed of 598, 614, 602, and 627 amino acids, respectively (Liu et al., 
1993). Mouse GAT3 and GAT4 correspond to the rat GAT-2 and GAT-3, 
respectively. This is due to the fact that mouse GAT2 in reality is a betaine 
transporter being homologous to the human and rat BGT-1 transporter 
(Schousboe et al., 2004). 
1.2.1. Subcellular location of GABA transporters 
GAT-1 is widely distributed in the central nervous system, being the most 
copiously expressed GAT in the cerebral cortex. Indeed specific GAT-1 
immunoreactivity is present in all cortical layers as well as in hippocampal 
formation (Minelli et al., 1995; Conti et al., 2004). GAT-1 is found both in 
neurons and astrocytes, and the majority of neurons expressing GAT-1 mRNA 
contain GAD67 immunoreactivity. However, a few pyramidal cells also express 
GAT-1 mRNA (Minelli et al., 1995). GAT-1 is also expressed in cortical 
astrocytes (Minelli et al., 1995), retinal Muller cells (Brecha and Weigmann, 
1994; Johnson et al., 1996) and in hippocampal astrocytic processes (Ribak et al., 
1996). It is important to mention that GAT-1 is located closely to GABAergic 
synapses, and it can also be found in glutamatergic neurons (Minelli et al., 1995).  
GAT-2 transporter is primarily located in the extrasynaptic region, and it can be 
found both in neuronal and non-neuronal cells (Conti et al., 1999; Conti et al., 
2004). 
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GAT-3 is localized to both neurons and astrocytes; however, it is primarily 
localized to the latter cell type (Durkin et al., 1995; Minelli et al., 1996; Conti et 
al., 2004). GAT-3 positive astrocytic processes are adjacent to axon terminals 
making synaptic contacts with cell bodies or dentrites, or are close to neuronal 
profiles that do not form synaptic contacts (Conti et al., 2004). 
BGT-1 can be found in dendritic process and cell body of hippocampal neurons 
(Zhu and Ong, 2004), being preferential located at extrasynaptic regions (Borden 
et al., 1995; Zhu and Ong, 2004). BGT-1 is also found on glia cells and in 
primary cultures of astrocytes (Zhu and Ong, 2004; Olsen et al., 2005). 
1.2.2. Structure and functioning of GABA transporters 
As it was previously mention, all GABA transporters are Na+/Cl- dependent 
transporters and belong to the SLC6 gene family. The SLC6 gene family also 
includes transporters of dopamine, 5-HT, norepinephrine and glycine (Gether et 
al., 2006). These transporters mediate-GABA transport together with sodium ion 
and chloride ion in an electrogenic process since they use the electrochemical 
gradient of sodium (generated by (Na++K+)-ATPase) between the outside and 
inside surfaces of the cell membrane to provide the thermodynamic energy 
required to pump neurotransmitters from low concentrations outside the cell to the 
much higher concentrations inside the cell (reviewed in Kanner, 2006). Under 
normal conditions, the stoichiometry for transport is 2 sodium ions : 1 chloride 
ion : 1 GABA molecule (Keynan and Kanner, 1988; Kavanaugh et al., 1992; 
Mager et al., 1993; Lu and Hilgemann, 1999) and they are able to generate a 
gradient in the order of 105 between the intra- and extracellular GABA 
concentration (Figure 1.2.1) (Beleboni et al., 2004). 
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The primary sequence of GAT-1, like of most SLC6 members, predicts twelve 
transmembrane domains (TM) connected by hydrophilic loops with the amino 
and carboxyl termini residing inside the cell (Guastella et al., 1990; Nelson et al., 
1990). GAT-1 is modified by asparagine-linked glycosylation (Radian et al., 
1986; Kanner et al., 1989; Keynan et al., 1992) and the model predicts a large 
extracellular loop between transmembrane helices 3 and 4 containning three N-
linked glycosylation sites (Guastella et al., 1990), that were later on confirmed 
(Figure 1.2.2) (Yamashita et al., 2005). 
 
  
1.2.1. The role of plasma membrane neurotransmitter transporters in synaptic transmission. 
Neurotransmitter (T), stored in synaptic vesicles, is released by fusion of the vesicles with the 
synaptic plasma membrane. After its diffusion across the synaptic cleft, it binds to postsynaptic 
receptors (PR), resulting in the opening of channels often present in the same structure as the 
receptor. Channel opening may lead to excitatory or inhibitory postsynaptic potentials (EPSP or 
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IPSP). Transmitter is removed from the cleft by re-uptake mediated by electrogenic sodium-coupled 
transporters (Tp), which also translocates other ions (*). In the case of the transporters of GABA, * 
is chloride, which moves in the same direction as sodium and the neurotransmitter. The main 
driving force for this process is the electrochemical gradient of sodium ions, which is maintained by 
the sodium pump (Na+/K+-ATPase, P). The transporters are located in the synaptic plasma 
membrane and also in the processes of glial cells, which are in close contact with the synapse. The 
activity of these transporters may be the subject of physiological regulation. This may be mediated 
by receptors for the same neurotransmitter (autoreceptors, AR) or by those of others 
(heteroreceptors, HR) (Adapted from Kanner, 1994). 
 
Several amino acids residues have a relevant role in GABA transporters 
functioning. For instance arginine R69 that has a positive charge is essential for 
transport, since its substitution with other amino acids including charged ones 
does not recover transport activity (Pantanowitz et al., 1993). Tryptophan W68, 
W222, and W230 when substituted with either serine or leucine resulted in a 90% 
reduction in transport activity. It appears that W68 and W222 are required for 
intrinsic activity, while W230 has been reported to be involved in plasma 
membrane targeting (Kleinberger-Doron and Kanner, 1994). Tyrosine Y140 
replacement is not tolerated even with the aromatic amino acids phenylalanine or 
tryptophan (Bismuth et al., 1997). Cysteine C74 located in EL1 is also suggested 
to be involved in the pore formation or GABA translocation (Figure 1.2.2) (Yu et 
al., 1998). 
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Figure 1.2.2. Schematic representation of the GABA transporter GAT-1 and the location of 
critical amino acids. Putative transmembrane segments are shown as rectangles. The potential 
glycosylation sites are indicated by branched lines. Critical residues of GAT-1 are indicated using 
the one-letter code and their positions are also given (Adapted from Kanner, 1994 with small 
modifications). 
 
One of the properties of neurotransmitter transporters, namely of GABA 
transporters, that was not taken into account in traditional models of synaptic 
function is that they can reverse and release neurotransmitter (Attwell et al., 1993; 
Levi and Raiteri, 1993). This reversal is a direct and expected consequence of the 
dependence of transporters on the transmembrane ion gradients (Figure 1.2.3). 
For a long time it was accepted that the reversion of GABA transporter would not 
occur under physiological condition, since it was only observed by using strong 
stimuli. For instance it was observed that, after removal of extracellular Ca2+, 
GABA release still occurs from cortical slices in response to an increase in K+ to 
50 mM, to exposure to 50 µM veratridine, or to high-frequency electrical 
stimulation (Szerb, 1979). This idea was confirmed later on when it was observed 
that GABA release still occurs in the absence of extracellular Ca2+ from cultured 
striatal neurons (Pin and Bockaert, 1989) and from cultured cortical neurons 
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(Belhage et al., 1993) in response to 55–56 mM K+ or 100 µM glutamate. 
However, the reversion of the GABA transporter can occur under physiological 
condition, and the initial idea that this reversal was only observed by using strong 
stimuli was probably a result of the relative insensitivity of the biochemical 
assays used to measure GABA release. As calculated (Richerson and Wu, 2003) 
and experimentally demonstrated (Gaspary et al., 1998; Wu et al., 2001; Wu et 
al., 2007) the reversal potential for GAT-1 is close to the normal resting potential 
of neurons, therefor a small level of depolarization can cause reversal of transport 
direction. GABA transporters can also reverse in presence of nipecotic acid, 
gabapentine and vigabatrin, being the last two anticonvulsants drugs (Wu et al., 
2001; Richerson and Wu, 2003; Wu et al., 2003).  
 
 
 
 
 
 
 
 
 
Figure 1.2.3. GABA transporters can reverse. Left panel, Schematic representation of the 
performed experiments in order to asses the reversion of GABA transporters. Patch-clamp 
recordings of GABAA receptor mediated currents were used to assay GABA release. Experiments 
were performed in 0 Ca2+ bath solution. When the GABA transporter reversed, by increasing [K-]o, 
GABA release was detected as a change in holding current in the recorded neuron. Right panel, 
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Stoichiometry of GAT-1. A thermodynamic reaction cycle involves coupled translocation of 2 Na+ 
ions, one Cl- ion and 1 GABA molecule. Thus GABA is normally driven up its concentration 
gradient using the energy stored in the Na+ and electrical gradients (Adapted from Richerson and 
Wu, 2003). 
 
1.2.3. Regulation of synaptic transmission by GABA transporters 
At first glance, the presence of transporters at or near the synapse, coupled with 
their role in transmitter removal, suggests that transporters are ideally situated to 
affect the magnitude and the time course of synaptic signalling. However, one of 
the difficulties of this hypothesis of transport-mediated influence on synaptic 
signalling comes from kinetic studies revealing that transport rates are slow, since 
the unitary transport rates are on the order of 10/sec for the Na+/Cl−-dependent 
transporter subfamily, including the GABA (Mager et al., 1993) and 
norepinephrine (NE) transporters (Galli et al., 1995), and 100–1000/sec for the 
Na+/K+-dependent glutamate transporter subfamily (Schwartz and Tachibana, 
1990). This slow turnover rates induces a transport that might affect normal 
synaptic signalling only at ‘‘slow’’ synapses; i.e., synapses in which responses are 
mediated through G protein-coupled receptors and signalling occurs on a time 
scale of hundreds of milliseconds. This led to the idea that uptake of transmitter 
could not be the only mechanism of shutting down neurotransmitter through 
transporters action. Presently some evidence suggests that transporters can alter 
synaptic responses on a millisecond time scale by sequestering transmitter at its 
binding sites within the transporter (Diamond and Jahr, 1997), effectively serving 
as a diffusion sink. Ample number of sites for GABA sequestration is provided by 
GAT-1 transporter present at nerve terminals calculated as high as 1000-2000 per 
square micron (Wang et al., 2002). This mechanism would allow for transporter-
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mediated signalling effects at “fast”, ligand-gated ion-channel synapses as well 
(Beckman and Quick, 1998). Indeed, upon blockade of GABA transporters there 
is an alteration of both the amplitude and decay of the response mediated through 
slow, “GABAB” receptors (Isaacson et al., 1993), and of the decay phase of the 
“fast” GABAA receptor-mediated response (Isaacson et al., 1993). If the number 
of GABA transporter binding sites is a crucial determinant of GABAergic 
transmission, then modulating the number of these sites via transporter trafficking 
will be important physiologically, not only by controlling synaptic GABA 
signalling but also potentially by regulating spillover GABA onto neighbouring 
synapses.  
More interesting is that recent reports continue to point to an important role of 
GABA transporters in regulating GABAergic inhibition. GAT-1 influences both 
phasic and tonic activation of GABAergic inhibition in striatal output neurons 
(Ade et al., 2008; Kirmse et al., 2008), demonstrating that GAT-1 is critically 
involved in the maintenance of low ambient [GABA] in this brain structure, as 
well as in maintaining phasic inhibition when there is failure of vesicular 
neurotransmitter release (Wu et al., 2007).  Also GAT-3 has a relevant role in 
GABAergic transmission since an acute blocked of GAT-3 under resting 
conditions is fully compensated by GAT-1. This indicates that GAT-3 might 
provide an additional uptake capacity when neuronal activity and GABA release 
are increased (Kirmse et al., 2009).  
GABA transporters look like to be involved in the GABAergic signaling between 
neurons and glial cells (Doengi et al., 2009). Activation of GABA uptake 
increases the intracellular [Na+], that afterwards reduce  Na+/Ca2+ exchange, 
thereby leading to a Ca2+ increase sufficient to trigger Ca2+ induced Ca2+ release 
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via inositol 1,4,5-trisphosphate (InsP3) receptors (Doengi et al., 2009). This role 
of GABA transporters, point out GABA as a mediator for neuron-glia signalling. 
1.2.4. Functional regulation of GABA transporters 
It is well established that GAT-1 functioning can be altered by a variety of 
initiating factors and signal transduction cascades, namely this functional 
modulation occurs through a variety of second messengers, such as kinases and 
phosphatases (Corey et al., 1994; Quick et al., 1997), transporter agonists and 
antagonists (Quick, 2002) and interacting proteins (Deken et al., 2000; Fan et al., 
2006). This modulation occurs in two ways: by changing the rate of transmitter 
flux through the transporter (the Michaelis constant, Km, for the transporter) or 
changing of functional transporters on the plasma membrane through the 
redistribution of transporters between intracellular locations and the plasma 
membrane.  
The first studies concerning the regulation of GAT-1 transporter were related with 
the activation of protein Kinase C (PKC). Gomeza and collaborators (1991) 
showed that PKC activation reduces GABA transport in glial cells; later on by 
using Xenopus oocytes cloned with GAT-1 transporter it was demonstrated that 
PKC modulates the activity of this transporter by regulating its subcellular 
redistribution (Corey et al., 1994).  This regulation by continuously traffic of 
GAT-1 to and from the plasma membrane (Deken et al., 2003) can occur through 
changes in the endocytosis and exocytosis rates, and/or the number of transporters 
available for recycling. Indeed, PKC decreases surface expression of GAT-1 in 
cortical neuronal cultures by increasing the endocytosis rate (Wang and Quick, 
2005; Cristovão-Ferreira et al., 2009). More interesting is that PKC modulation of 
GABA transport in oocytes coexpressing GAT-1 and total rat brain mRNA can be 
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eliminated by injecting antisense synaptophysin and syntaxin oligonucleotides, 
being the antisense nucleotides strings of oligonucleotides that are complementary 
to "sense" strands of regions of synaptophysin and syntaxin, and that bind to and 
inactivate synaptophysin and syntaxin; injection of botulinum toxins, which 
inactivate proteins involved in vesicle release and recycling, such as SNAP-25, 
syntaxin and synaptobrevin (Schiavo et al., 1992; Blasi et al., 1993b; Blasi et al., 
1993a), also eliminates PKC-mediated modulation; and coexpression of GAT-1 
and syntaxin 1A cRNA is sufficient to permit PKC-mediated modulation (Quick 
et al., 1997). Indeed it was later on shown that syntaxin-1 interaction with GAT-1 
results in a decrease of transport rates (Beckman et al., 1998; Lin et al., 1998; 
Deken et al., 2000), and that SNAP-25 efficiently inhibits GAT-1 reuptake 
function in the presence of syntaxin 1A (Fan et al., 2006). 
Tyrosine kinases also modulate GAT-1 since their inhibition induces an 
intracellular accumulation of the transporter that is correlated with an increase of 
the internalization rate (Law et al., 2000; Whitworth and Quick, 2001). Thus, the 
translocation o GABA transporter from/to the plasma membrane is related with 
the phosphorylation states of the transporter (Quick et al., 2004). GAT-1 is 
phosphorylated on serine residues in a PKC-dependent manner, however this state 
is only revealed when GAT1 tyrosine phosphorylation is eliminated or greatly 
reduced. The relative levels of serine phosphorylation and tyrosine 
phosphorylation are negatively correlated, which indicates that the amount of 
serine phosphorylation is regulated by agents that affect tyrosine phosphorylation, 
and vice versa (Quick et al., 2004). So, GAT-1 can exist in either of two mutually 
exclusive phosphorylation states and the relative abundance of these states 
determines in part the relative subcellular distribution of the transporter (Quick et 
al., 2004): an increase in the relative amount of GAT-1 that is tyrosine 
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phosphorylated correlates with a relative increase in GAT-1 surface expression; 
an increase in the relative amount of GAT-1 that is serine-phosphorylated 
correlates with an accumulation of intracellular GAT-1. 
Extracellular GABA can also regulate GABA transport (Bernstein and Quick, 
1999) and this regulation depends on syntaxin-1 (Quick, 2002), providing a 
feedback mechanism for the control of neurotransmitter level at the synapse, since 
GABA transporter fine-tunes its function in response to extracellular GABA. 
Extracellular GABA induces an up-regulation of the transport that is correlated 
with an increase in surface expression due to a slowing of GAT-1 internalization 
rate, while transporter inhibitors down-regulate this transport (Bernstein and 
Quick, 1999). The described mechanism occurs on a time scale of minutes and 
requires in part direct tyrosine phosphorylation of the transporter (Whitworth and 
Quick, 2001). In contrast the presence of GABA on a longer time scale causes a 
net decrease in GAT surface expression, which suggests that multiple pathways, 
perhaps converging upon mechanisms involving protein phosphorylation, act to 
regulate GAT-1 expression in neurons (Hu and Quick, 2008). 
1.2.5. Pathological implication of GABA transporters 
In order to maintain the brain function at all levels, it is fundamental to tightly 
regulate the synthesis, release, and removal of synaptically released GABA 
(Madsen et al., 2010).  Thus, there is considerable medical interest on GABA 
transporters, since they function to regulate neurotransmitter activity by removing 
GABA from the synaptic cleft, and specific transporter inhibitors can be 
potentially used as novel drugs for neurological disease.  
One of the most studied disorders concerning GABA transporters is epilepsy. 
Epilepsy is a heterogeneous neurological disorder characterized by the onset of 
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spontaneous convulsive and non-convulsive seizures. A common feature in 
epilepsy seems to involve hyperexcitable neurons which discharge in a highly 
synchronized manner to produce a seizure, being suggested that seizure activity is 
a consequence of an imbalance between the inhibitory and excitatory 
neurotransmission (Dalby and Mody, 2001). Interestingly in patients with 
temporal lobe epilepsy there is an increase in GAT-3 expression in astrocytes and 
a decrease of GAT-1 expression in nerve terminals (Lee et al., 2006), suggesting 
that transport regulation may differ in different cell types. Nevertheless, 
attenuation of GABA removal, by inhibiting GABA transporters, will prolong the 
effect of this inhibitory transmitter, leading to an attenuation of seizure activity. 
This led to the development of inhibitors of GABA uptake, and the first GABA 
uptake inhibitor to be marketed as a novel antiepileptic was tiagabine (Schachter, 
1999; Iversen, 2006). It is worthwhile to note that tiagabine, launched initially for 
use in epilepsy, is now being investigated for other possible indications, in the 
treatment of psychosis, generalized anxiety, sleep in the elderly and drug 
addiction (Iversen, 2004). 
It is therefore highly likely that drugs acting on GABA transporters may become 
potential therapeutic candidates for the treatment of other neurologic and 
psychiatric conditions associated with dysfunction of the GABAergic system; 
e.g., anxiety, sleep disorders, chronic pain, post-traumatic stress disorder, 
migraine, and others. 
1.3. Neuron-Astrocyte communication and the tripartite synapse 
The concept of tripartite synapse rises from the recognition of a bidirectional 
communication between neurons and astrocytes at the synapse, in which the 
astrocyte, in addition to pre- and postsynaptic compartments, is a functional 
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component of the synapse (Agulhon et al., 2008). ATP, glutamate and GABA are 
considered important molecules involved in this bidirectional communication 
between neurons and astrocytes, since they are stored in, and released from, 
synaptic vesicles and glial cells at mM concentrations, thereby affecting 
neurotransmitter release and rising glial calcium concentration, respectively 
(Neary and Zhu, 1994; Lechner et al., 2004; Hamilton and Attwell, 2010). The 
calcium increase in astrocytes promotes the release of gliotransmitters, such as 
classical transmitters, chemokines, cytokines and peptides (Halassa and Haydon, 
2010), including ATP (Newman, 2001; Pryazhnikov and Khiroug, 2008), 
glutamate (Nedergaard, 1994; Parpura et al., 1994), D-serine (Mothet et al., 2005) 
and BDNF (Bergami et al., 2008). All these gliotransmiters can directly activate 
neuronal receptors and modulate synaptic transmission (Figure 1.3.1).  
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Figure 1.3.1. Schematic representation of the tripartite synapse. When neurotransmitters are 
released from the presynaptic terminal of a neuron, astrocytic receptors are thought to be activated, 
leading to a rise in calcium ions in the astrocyte and the release of various active substances 
(gliotransmitters), such as ATP, which act back on neurons to either inhibit or enhance neuronal 
activity. Astrocytes also release proteins, which control synapse formation, regulate presynaptic 
function and modulate the response of the postsynaptic neuron to neurotransmitters (Adapted from 
Allen and Barres, 2009). 
 
Until now two mechanisms have been proposed where GABA has a preponderant 
role in neuron/astrocyte communication. The evoked release of GABA by 
repetitive firing of interneurons activates GABAB receptors on astrocytes, which 
increase their [Ca2+]i. This leads to the release of glutamate from astrocytes, 
which acts on presynaptic ionotropic receptors to increase the probability of 
GABA release onto pyramidal cells (Kang et al., 1998). On the other hand 
astrocytes may also have a role in heterosynaptic depression in the hippocampus. 
The released glutamate from excitatory afferents to CA1 pyramidal cells activates 
inhibitory interneurons to release GABA. GABA inhibits postsynaptic neurons 
but also activates astrocyte GABAB receptors, raising astrocytic [Ca2+]i, which 
triggers the release of glutamate from the astrocytes and thus depresses 
transmitter release from other afferents (Andersson et al., 2007). This 
heterosynaptic depression is mediated by group II and III mGluRs on the 
presynaptic terminals of the afferents (Figure 1.3.2). A third mechanism was 
described in astrocytes of olfactory bulb slices. In this case GABA evoked Ca2+ 
transients in astrocytes through GABA transporter, since GABA uptake mediates 
a Na+ rise in the cells that reduce Na+/Ca2+ exchange, thereby leading to a Ca2+ 
increase sufficient to trigger Ca2+-induced Ca2+ release via InsP3 receptors (Figure 
1.3.3) (Doengi et al., 2009). 
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Glutamate potentiating inhibition Heterosynaptic depression by glutamate 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.2. Proposed mechanisms where GABA is implicated in functional effects of 
glutamate, d-serine and ATP release from astrocytes. Left panel, Glutamate potentiating 
inhibition. Glutamate release from astrocytes, triggered by GABA activating astrocyte GABAB 
receptors, increases presynaptic GABA release. Right panel, Heterosynaptic depression by 
glutamate. Stimulating the Schaffer collaterals evokes GABA release from hippocampal 
interneurons, which activates GABAB receptors on astrocytes. The resulting [Ca2+]i increase releases 
glutamate, which acts on presynaptic group II–III mGluRs to suppress glutamate release from other 
afferents (Adapted from Hamilton and Attwell, 2010). 
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Figure 1.3.3. Scheme of the mechanism of GABA uptake-mediated Ca2+ signaling in 
astrocytes. GABA uptake mediated by glial GABA transporter (GAT) is coupled with an 
intracellular Na+ rise (1). The increased [Na+]i reduces the inwardly directed electrochemical Na+ 
gradient and, hence, the efficacy of the Na+/Ca2+ exchanger (NCX) (2). Ca2+ accumulates in the 
astrocyte due to reduced Ca2+ extrusion by NCX (3). The increase in intracellular Ca2+ triggers Ca2+ 
-induced Ca2+ release from the endoplasmic reticulum (ER) via InsP3 receptors (4) (Adapted from 
Doengi et al., 2009). 
 
1.3.1. Astrocytes 
Glia refers to a diverse set of cell types phenotypically diverse that are likely to 
carry out distinct functions in neurophysiology, and were first described in mid-
19th century by Virchow, Golgi, Müller, Deiters and others (Kettenmann and 
Ransom, 2005). Glial cells are electrically unexcitable cells in the nervous system 
and have long been considered to be supporting cells with little direct impact on 
neuronal performance. Indeed when glia was first described there was 
considerable debate as to whether glia was a connective tissue or a true population 
of cells (see Somjen, 1988).  This idea began to change when it was found that 
glial cells express a large number of G protein-coupled receptors that activate a 
diverse array of intracellular signalling cascades (McCarthy and de Vellis, 1978; 
Van Calker et al., 1978; Porter and McCarthy, 1997).  Later on, it was recognized 
that astrocytes, the major class of glial cells in the mammalian brain, participate in 
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synaptic transmission and contribute to information processing, since they can 
control the ionic environment of the neuropil and control the supply of 
neurotransmitters to the synapses (Haydon and Carmignoto, 2006; Halassa et al., 
2007a; Halassa and Haydon, 2010), leading to a stabilization of cell-to-cell 
communication.   Astrocytes due to their ability to release neurotrophic factors 
and gliotransmitters, among others, are also involved in the active control of 
synaptogenesis and plasticity, the regulation of blood flow (Koehler et al., 2009; 
Carmignoto and Gomez-Gonzalo, 2010) and the promotion of myelination 
(Barres, 2008). 
There are four major groups of glial cells in the nervous system: (1) Schwann 
cells and oligodendrocytes, which produce and wrap layers of myelin around 
axons in the peripheral and central nervous systems, respectively; (2) microglia, 
the immune cell type of the nervous system, which participate in inflammatory 
responses; (3) nerve/glial antigen 2 (NG2)-positive glia, which include 
oligodendrocyte and astrocyte progenitor cells as well as NG2+ cells that persist 
in the mature brain; and (4) astrocytes (Agulhon et al., 2008). 
In 1893 Lenhossek introduced the term astrocyte to refer to starshaped glial cells 
(Kettenmann and Ransom, 2005). Astrocytes can be found in CNS in a 
contiguous and nonoverlapping manner and are divided into several groups 
(Reichenback and Wolburg, 2005): protoplasmic astrocytes (type-I), fibrous 
astrocytes (type-II), velate astrocytes, perivascular astrocytes, radial astrocytes, 
Bergmann glia, Müller glia, marginal glia, tanycytes and various forms of 
ependymal glia.   
Protoplasmic astrocytes are found in gray matter and wrap neuronal cell bodies 
and synapses (estimates suggest a single human astrocyte wraps more than 
270,000 synapses) (Ventura and Harris, 1999; Bushong et al., 2002; Halassa et 
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al., 2007b); whereas fibrous astrocytes, which are found in white matter, in optic 
nerve and in the nerve fiber layer of mammalian vascularise retina, have 
processes that wrap nodes of Ranvier (Waxman, 1986; Butt et al., 1994; 
Sofroniew and Vinters, 2010). Therefore protoplasmic astrocytes are intimately 
associated with neuronal cell bodies and synapses, whereas fibrous astrocytes are 
associated with neuronal axons.  
Radial astrocytes are common in spinal cord and brain of lower vertebrates, 
Bergmann glia are the radial astrocytes of the cerebellum in all vertebrates, 
Müller glia are the radial astrocytes of the retina, velate astrocytes were described 
in the granule layer of the cerebellum, perivascular astrocytes and marginal glia 
are near pia matter and may form several layers of endfeet, tanycytes are the most 
commom glia in lower vertebrates (Reichenback and Wolburg, 2005). 
1.4. Neurotrophins 
The history of neurotrophins started in 1950s when Levi-Montalchini, Cohen and 
Hamburger isolated the nerve growth factor (NGF) from the snake venom (Cohen 
et al., 1954). Only 30 years later was identified other neurothopin, the brain-
derived neurotrophic factor (BDNF) (Barde et al., 1982) and for now there are 
four neurotrophins characterized in mammals: NGF, BDNF, neurotrophin-3 (NT-
3) , and neurotrophin-4 (NT-4), which are derived from a common ancestral gene 
and are similar in sequence and structure (e.g. Hallbook, 1999). Since their 
discovery neurotrophins were extensively studied and they were primarily seen as 
key regulators of growth, survival and differentiation of neurons (Chao, 2003; Lu 
et al., 2008). More recent studies demonstrated that neurotrophins cause long-
term structural and molecular changes at synapses, which are crucial not only to 
development but also to synaptic function and plasticity in the adult brain 
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(Vicario-Abejon et al., 2002; Lu et al., 2008). On the other hand, neuronal activity 
plays a crucial role in the synthesis, release and effects of neurotrophins (for 
example see (Zafra et al., 1990; Figurov et al., 1996; Nagappan and Lu, 2005).  
Of the four neurotrophins, BDNF actions on central neurons have been best 
characterized. The synthesis of BDNF is highly regulated since, for instance,  the 
Bdnf gene is comprised of at least eight distinct promoters that initiate 
transcription of multiple distinct mRNA transcripts (Aid et al., 2007). Through 
the use of alternative promoters, splicing and polyadenylation sites, at least 18 
transcripts can be produced, but remarkably, each encodes an identical initial 
BDNF protein product (Greenberg et al., 2009). Furthermore, the Bdnf transcripts 
are polyadenylated in two differet sites: those with a short 3’UTR and those with 
a long 3’UTR (Timmusk et al., 1993), having these two type of Bdnf mRNAs 
distinct subcellular compartments on neurons. The short 3’UTR Bdnf mRNA is 
restricted to the soma, whereas the long 3’UTR Bdnf mRNA is also targeted to 
dendrites where BDNF can be locally translated (Figure 1.4.1) (An et al., 2008; 
Greenberg et al., 2009).  
Although BDNF action can be altered through mechanisms of regulation of Bdnf 
mRNA, it can also be modified at the protein level. BDNF is initially synthesized 
as a precursor protein (preproBDNF) in endoplasmic reticulum. Following 
cleavage of the signal peptide, proBDNF is transported to the Golgi for sorting 
into either constitutive or regulated secretory vesicles. ProBDNF can be cleaved 
to mature BDNF (mBDNF) by furin within the Golgi and by proconvertases 
within the secretory vesicles (Mowla et al., 1999). It has long been thought that 
only secreted mBDNF is biologically active, and proBDNF is exclusively 
localized intracellularly, serving as an inactive precursor. However, recent 
observations of proBDNF secretion and its conversion to mBDNF in vitro by 
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plasmin and matrix metalloproteases suggest that proBDNF may be biologically 
active (Pang et al., 2004; Yang et al., 2009), although the efficiency of 
intracellular cleavage is controversial (Matsumoto et al., 2008) and may vary 
among neuronal cell types. 
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Figure 1.4.1. Production and processing of BDNF in the central nervous system. (a) ProBDNF 
may be processed to mature BDNF by several cellular mechanisms. ProBDNF can be cleaved 
within the endoplasmic reticulum by furin (1) and in regulated secretory vesicles by proconvertase 
enzymes (2). If proBDNF reaches the extracellular milieu, it can be processed by plasmin, and the 
mature BDNF produced can then activate cell surface TrkB receptors (3). Alternatively, 
extracellular proBDNF can bind p75NTR and become endocytosed and then cleaved to produce 
mature BDNF that either activates TrkB within endosomes (5) or is recycled to the cell surface (6). 
(b) The site of BDNF translation within the neuron may determine the form of BDNF released. 
BDNF mRNA with a short 3 UTR accumulates in the neuronal soma, whereas BDNF mRNA with 
a long 3 UTR is trafficked to dendrites. (Adapted from Barker, 2009). 
 
1.4.1. Neurotrophin receptors 
Neurotrophins mediate their effects through binding to two different families of 
receptors (Figure 1.4.2): 
1. the high-affinity tropomyosin-related kinase (Trk) receptors, which 
belong to the tyrosine kinase family of receptors. There are three types of 
Trk receptors, namely TrkA that specifically bind NGF, TrkB that binds 
BDNF and NT-4 and TrkC that recognize NT-3. 
2. the p75 neurotrophin receptors (p75NTR), which are single transmembrane 
proteins of the superfamily of tumor necrosis factor (TNF)  (Arevalo and 
Wu, 2006). All neurotrophins bind p75NTR with equal affinity, however 
neurotrophins are recognized with low affinity (100-fold less that the Trk 
receptors) and proneurotrophins with high affinity (Lee and Chao, 2001).  
BDNF binds as dimmer to TrkB receptor triggering the dimerization of the 
receptor (Figure 1.4.2). The activation of TrkB leads to the autophosphorylation 
of the receptor, at multiple tyrosine residues in the cytoplasmic domain of the 
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receptor, and the activation of intracellular signaling cascades. The Src 
homologous and collagen-like (Shc) adaptor protein links the activated TrkB 
receptor to two separate intracellular signaling pathways (Figure 1.4.2.): neuronal 
survival requires Shr binding to the TrkB receptor, which results in increases in 
phosphatidylinositol 3-kinase (PI3K) and Akt activities, whereas neuronal 
differentiation requires the phosphorylation of Shr that leads to increases in the 
activity of RAS and the extracellular signal-regulated kinase (ERK). In addition, 
phospholipase C-γ (PLC-γ) binds to activated TrkB receptor and initiates an 
intracellular cascade that to a subsequent activation of protein kinase C- (PKC-δ) 
(Chao, 2003; Huang and Reichardt, 2003; Reichardt, 2006). 
 
Figure 1.4.2. Neurotrophin receptors and intracellular cascade activated in neurotrophin 
signalling. Trk receptors mediate differentiation and survaival siganling through extracellular 
signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K) and phospholipase C-γ (PLC-γ) 
pathways. The p75 receptor predominantly signals to activate NF-B and Jun N-terminal kinase 
(JNK) (Adapted from Chao, 2003). 
Modulation of GAT-1 transporters by BDNF and A2A receptors 
 
 32
Different TrkB receptor isoforms are generated by alternative splicing, namely 
one full-length form of TrkB (TrkB-fl) with an extracellular ligand binding 
domain, a single transmembrane domain, and a typical tyrosine kinase-containing 
intracellular domain (Berkemeier et al., 1991; Klein et al., 1991; Middlemas et al., 
1991; Soppet et al., 1991; Squinto et al., 1991) and three truncated TrkB (TrkB-
t1, TrkB-t2 and TrkB-t-Shr) isoforms with the same extracellular and 
transmembrane domains as TrkB-fl but with “truncated” intracellular domains 
lacking the kinase domain (Figure 1.4.3) (Klein et al., 1990; Middlemas et al., 
1991; Shelton et al., 1995; Stoilov et al., 2002). The TrkB-t1 and TrkB-t2 have a 
“truncated” intracellular domain with 23 and 21 amino acids, respectively, lacking 
the kinase domain (Klein et al., 1990; Middlemas et al., 1991) and being the last 
11 and 9 residues isoform-specific, respectively. The TrkB-t-Shc contains a Shc-
binding site in the juxtamembrane domain similar to TrkB-fl, but it lacks the 
kinase domain and has a unique truncated C terminus (Stoilov et al., 2002). 
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Figure 1.4.3. TrkB isoforms structure and functional domains. The extracellular portion of the 
receptor is conserved, however the intracellular domain differs among the isoforms. TrkB-fl 
contains a tyrosine kinase domain, a SHC-binding domain, and a PLC--binding domain, TrkB SHC 
contains a SHC-binding domain and TrkB-t (TrkB-t1 and TrkB-t2) does not have any functional 
domain (Adapted from Ansaloni et al., 2011). 
 
1.4.2. Fast BDNF actions at synapse 
Most of the trophic and plastic actions of BDNF are mediated by TrkB receptors 
which trigger a complex signalling cascade leading to changes in transcription 
and in synthesis of key molecules involved in growth, survival and differentiation 
of neurons (Vicario-Abejon et al., 2002). It is commonly wide accepted nowadays 
that activation of TrkB receptor can also modulate neuronal activity since 
neurotrophins are able to induce structural and molecular changes at synaptic 
level that influence not only the neuronal development but also the synaptic 
function and plasticity of the adult brain.  
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Thus it has been shown that BDNF also has fast actions on synapses that occur in 
a time scale of less than 1 h and lead to facilitation of synaptic transmission (Kang 
and Schuman, 1995b; Diógenes et al., 2004; Pousinha et al., 2006; Diogenes et 
al., 2007; Fontinha et al., 2008; Assaife-Lopes et al., 2010), facilitation of end 
plate potential (Pousinha et al., 2006) and log-term potentiation (LTP) (Fontinha 
et al., 2008). These relatively fast synaptic actions of BDNF may also require de 
novo protein synthesis, as it has been shown to occur in relation to the BDNF-
induced increases in AMPA (Caldeira et al., 2007b) and NMDA (Caldeira et al., 
2007a) receptor levels in the cytoplasmic membrane of cultured neurons or 
require the translocation of these receptor to lipid rafts (Assaife-Lopes et al., 
2010). On the other hand some synaptic BDNF actions result from a local and 
very fast action at synapses; indeed, this neurotrophin is able to facilitate 
glutamate release from synaptosomes (Sala et al., 1998; Canas et al., 2004; 
Pereira et al., 2006; Assaife-Lopes et al., 2010), which lack the somatic 
machinery for modulation at the gene transcription level. All the different action 
of BDNF can be related with the fact that cellular responses to BDNF differed 
markedly depending on how BDNF is delivered, since in cultured rat 
hippocampal neurons acute or gradual increases in BDNF elicited transient or 
sustained activation of TrkB receptor and its downstream signaling, respectively 
(Ji et al., 2010). Indeed transient TrkB activation promoted neurite elongation and 
spine head enlargement, whereas sustained TrkB activation facilitated neurite 
branch and spine neck elongation. On the other hand, also in hippocampal slices, 
fast and slow increases in BDNF enhanced basal synaptic transmission and LTP, 
respectively (Ji et al., 2010). 
The above described BDNF effects are mediated by TrkB-fl receptors; 
nevertheless accumulating evidence suggest that truncated isoforms of TrkB 
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receptors, even not having the characteristic catalytic domain of the TrkB-fl 
receptor, may be coupled to an intracellular signaling pathway(s). TrkB-t1 
isoform is the most studied of the truncated receptors. Initially it was thought that 
due to the lack of a kinase domain Trkb-t1 could not signal to the cytoplasm, 
working this receptors as a buffer for BDNF since TrkB-t1 form could bind to 
BDNF, sequestering it, so that it cannot bind TrkB-fl (Biffo et al., 1995; 
Bothwell, 1995) or by acting as a dominant negative inhibitor of TrkB-fl signaling 
(Eide et al., 1996; Ninkina et al., 1996; Haapasalo et al., 2001). This idea started 
to change when it was shown that, for instance, a short cytoplasmic domain of 
TrkB-t is required for BDNF-induced signal transduction (Baxter et al., 1997). It 
has also been shown that in cultured astrocytes, TrkB-t mediates rapid calcium 
transient in response to brief application of BDNF that results from the activation 
of phospholipase C and release of calcium from inositol trisphosphate-sensitive 
stores (Rose et al., 2003). This conclusion came from the observation that the 
calcium transient was insensitive to a tyrosine kinase inhibitor and was present in 
mutant mice lacking TrkB-fl (Rose et al., 2003). Signaling via TrkB-t may also 
play roles in the formation of dendritic filopodia in hippocampal neurons 
(Hartmann et al., 2004). Truncated TrkB-t1 regulates the morphology of 
neocortical layer I astrocytes in adult rat brain slices (Ohira et al., 2007) and at 
least in primary astrocyte cultures TrkB-t1 regulates astrocytic morphology via 
Rho GTPases (Ohira et al., 2005). The importance of these two TrkB isoforms in 
the present study concerns with the fact that some authors defend that astrocytes 
only express TrkB-t form (Rose et al., 2003; Bergami et al., 2008). 
Concerning the BDNF effects upon GABA transporters it is known that BDNF 
increases GABA uptake in hippocampal neuron cultures, resulting this increase 
from a redistribution of the transporter from intracellular locations to the cell 
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surface (Law et al., 2000). On the other hand BDNF inhibits release of GABA 
from isolated nerve terminals, and this effect occurs through reversal of GABA 
transporters (Canas et al., 2004). 
1.5. Adenosine  
Adenosine is an ubiquitous molecule present in all cells and with important 
modulatory functions within the CNS, where it is involved in the inhibitory tone 
of neurotransmission and in neuroprotective action in pathological conditions. 
This molecule is a nucleoside composed of a molecule of adenine attached to a 
ribose sugar molecule (ribofuranose) through a a -N9-glycosidic bond. 
 
 
 
 
 
Figure 1.5.1. Molecular structure of adenosine molecule. 
 
1.5.1. Adenosine synthesis 
Adenosine is continuously formed at extra and intracellular level being 
extracellular adenosine obtained in three ways: (1) release of adenosine by 
facilitated diffusion though nucleoside transporters after an increase of the 
intracellular levels of adenosine or a reversal of sodium gradient, (2) extracellular 
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conversion of released adenine nucleotides (especially adenosine triphosphate, 
ATP) into adenosine through the ectonucleotidade pathway (Zimmermann and 
Braun, 1999) and (3) extracellular formation of adenosine after release of cyclic 
adenosine monophosphate (cAMP) and its breakdown by ecto-phosphodiesterase 
pathway. (1) and (2) above are the predominant ones and the relative importance 
of each of them depends on the metabolic state of the cells and, in the case of 
neuronal cells, their excitability status. Thus, high frequency neuronal firing and 
astrocytic stimulation leads to predominance of pathway (2) for extracellular 
adenosine formation   (Dunwiddie and Masino, 2001; Latini and Pedata, 2001; 
Fredholm et al., 2005).  
The intracellular production of adenosine is mediated by the cytosolic enzyme 5'-
nucleotidase that desphosphorylates AMP or by hydrolyses of S-adenosil-
homocistein (SAH) mediated by the enzyme SAH hydrolase (Figure 1.5.2). The 
synthesized adenosine is afterward transported for the extra cellular medium 
through bidirectional specific transporters that can therefore regulate extracellular 
concentration of adenosine. There are two main categories of nucleoside 
transporters: (1) equilibrative nucleoside transporters, which carry both purine and 
pyrimidine nucleosides across cell membranes in either direction and following 
their concentration gradient; (2) concentrative nucleoside transporters that 
mediate the influx of nucleosides coupled under the force of transmembrane 
sodium gradient. In the CNS the equilibrative type of nuleoside transporter 
appears to dominate (for a review see Thorn and Jarvis, 1996). On the other hand, 
the enzyme responsible for the extracellular formation of adenosine is the ecto-5’-
nucleotidase, which is linked to the plasma membrane with its active site exposed 
in the extracellular space. The activity of ecto-5’-nucleotidase is associated with 
both neuronal and astrocyte cells , several works demonstrated that it is mainly 
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associated with astrocytes, oligodendrocytes and microglia (for a review see 
Latini and Pedata, 2001). 
In basal condition extracellular adenosine concentration is in the range of 25-250 
nM (Dunwiddie and Masino, 2001), and this concentration is sufficient to 
tonically activate a substantial fraction of A1 and A2A receptors. Indeed, in normal 
physiological conditions adenosine has several roles, which include regulation of 
sleeping, regulation of general state of arousal as well as local neuronal 
excitability and coupling cerebral blood flow to energy demand. However in 
pathological conditions extracellular brain concentrations of adenosine are 
markedly elevated by several types of stimuli, namely hypoxia, ischemia and 
epilepsy. Many of the effects of adenosine that are observed to a minor extent 
under normal conditions (e.g. presynaptic inhibition of glutamate release) are 
greatly augmented during pathological events and are neuroprotective in that 
context. In addition to having acute protective effects, transient activation of 
adenosine receptors offers protection against damage induced by a subsequent 
hypoxic or ischemic event (Newby et al., 1985; de Mendonça et al., 2000; 
Fredholm et al., 2005). Thus, the actions mediated by adenosine are related with it 
capacity to modulate direct release of neurotransmiters, synaptic transmission and 
plasticity, as well as, to modulate other receptor and modulator molecules, such as 
neurotrophins, dopamine and cannabinoids (Sebastião and Ribeiro, 2009). 
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Figure 1.5.2 Pathways of adenosine production, metabolism and transport. Adenosine is 
produced intra- and extracellular by nucleotidase enzymes activity. Bidirectional specific 
transporters, namely equilibrative nucleoside transporters or concentrative nucleoside transporters, 
regulate extracellular concentration of adenosine. Abbreviations are as follow: ADA, adenosine 
deaminase; AK, adenosine kinase; cAMP, cyclic adenosine monophosphate; SAH, S-adenosyl 
homocysteine; ENT, equilibrative nucleoside transporters (Adapted from Meijer et al., 2008). 
 
1.5.2. Adenosine receptors 
Until now four different adenosine receptors have been identified and cloned, 
namely adenosine A1, A2A, A2B and A3 receptors (Fredholm et al., 2001). All four 
receptors are G protein coupled receptors: A1 and A3 are negatively coupled to 
adenylyl cyclase through the Gi/o protein -subunits, whereas A2A and A2B are 
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positively coupled to adenylyl cyclase through Gs proteins (Figure 1.5.3). 
Adenosine receptors also have different affinities for adenosine: A1 and the A2A 
exhibit a higher affinity than A2B and A3, which are considered of low affinity 
(Dunwiddie and Masino, 2001). The A3 receptor is a high affinity receptor in 
humans but has a low density in most tissues (Ribeiro et al., 2002).  
 
 
 
 
 
 
 
Figure 1.5.3 Classification of adenosine receptors and their coupling to the enzyme adenylyl 
cyclase. A1 and A3 receptors are mainly coupled to Gi proteins, while A2A and A2B are mainly 
coupled to Gs proteins, either inhibiting or stimulating the enzyme adenylyl cyclase, respectively. 
Adenosine receptors bind adenosine with different affinities (Adapted from Sitkovsky et al., 2004).  
 
The four adenosine receptors are differentially expressed in different areas of 
CNS. Adenosine A1 receptor is highly expressed in brain cortex, cerebellum, 
hippocampus, and dorsal horn of spinal cord (Figure 1.5.4), whereas A2A receptor 
is highly expressed in the striato-pallidal GABAergic neurones and olfactory 
bulb, being expressed in lower levels in other brain regions (see Ribeiro et al., 
2002). Although A2A receptors are expressed in much low density in the 
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hippocampus (Cunha et al., 1994; Cunha et al., 1996) they can be activated by 
extracellularly generated adenosine in order to facilitate neurotransmitter release 
(Cunha et al., 1999). The A2B receptor has a low level of expression in the brain 
(Dixon et al., 1996). The A3 receptor has apparently intermediate levels of 
expression in the human cerebellum and hippocampus and low levels in most of 
the brain (see Fredholm et al., 2001). All four adenosine receptors are detected in 
astrocytes (Bjorklund et al., 2008), and all have been reported to be expressed in 
microglial cells or microglial cell lines (Hammarberg et al., 2003; van Calker and 
Biber, 2005; Dare et al., 2007). In the hippocampal neurons both A1 and A2A 
receptors are predominantly, but not exclusively, located presynaptically (Rebola 
et al., 2003; Rebola et al., 2005a; Rebola et al., 2005b), while in striatum the A2A 
receptors are located presynatically. In hippocampal presynaptic nerve terminals 
has been shown that A1 receptors do not directly modulate GABA release (Cunha 
and Ribeiro, 2000) but influence the action of other neuromodulators upon GABA 
release (Cunha-Reis et al., 2008). On the other hand a facilitation of GABA 
release was observed when A2A receptors were activated (Cunha and Ribeiro, 
2000). Adenosine receptos expressed in nerve terminals also modulate GABA 
transporters: A2A receptors, but not A1 or A2B receptors, enhance GABA uptake 
and this occurs through activation of the adenylyl cyclase/cAMP/protein kinase A 
transducing system (Cristovão-Ferreira et al., 2009). 
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Figure 1.5.4 Distribution of adenosine receptors in the main regions of the central nervous 
system. Adenosine receptors are differentially expressed in different areas of the central nervous 
system (Adapted from Ribeiro et al., 2002). 
 
1.5.3. Interaction between A2A receptors and TrkB receptors 
Activation of G-protein coupled receptors (GPCRs) and tyrosine kinase receptors 
(RTKs) generate independent responses with different biological effects as well as 
different signaling pathways, nevertheless their actions are tightly related (Pyne et 
al., 2007). So the action of GPCR agonist on RTKs usually facilitate/sensitize 
RTKs for their cognate ligands, increase the synthesis of the endogenous RTK 
ligand and activate RTKs in the absence of ligand, a phenomenon called 
transactivation (for a review see Sebastião et al., 2010). 
Concerning interactions between A2A receptors and TrkB receptor it has been 
shown that activation of A2AR or pituitary adenylyl cyclase-activating polypeptide 
receptor 1 (PAC1) were able to directly activate TrkA and TrkB receptors in the 
absence of NGF or BDNF (transactivation), respectively (Lee and Chao, 2001; 
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Lee et al., 2002). This transactivation requires long-term incubation (3h) with A2A 
receptor agonistand involves mostly immature, intracellular Trk receptors located 
in Golgi-associated membranes (Lee and Chao, 2001; Lee et al., 2002). 
Furthermore, direct activation of Trk receptors by adenosine requires cAMP, 
increases in intracellular calcium, protein synthesis and activation of Fyn, a 
member of the Src-family kinases. In fact, Fyn is able to directly phosphorylate 
TrkB receptors in response to adenosine, and is colocalized with intracellular 
TrkB receptors (Rajagopal and Chao, 2006). It has also been recently 
demonstrated that activation of A2A receptor induces translocation of TrkB 
receptor to lipd rafts (Assaife-Lopes, 2010), through a mechanism most probably 
independent of TrkB transactivation. 
Besides inducing TrkB transactivation, A2AR activation also increase the 
biological effects of a RTK ligand, i.e., activation of A2ARs is able to trigger 
various TrkB-mediated BDNF actions in the nervous system.  It is known that 
presynaptic depolarization increases extracellular adenosine levels, as well as 
enhances intracellular cyclic AMP, the canonical A2A receptor transducing 
pathway, triggering synaptic actions of BDNF (Boulanger and Poo, 1999a; 
Boulanger and Poo, 1999b). Indeed, several works demonstrated that adenosine 
A2A receptor activation is a crucial requisite for the functioning of TrkB receptor 
at synapse. This has been shown for the actions of BDNF on synaptic 
transmission (Diógenes et al., 2004; Diógenes et al., 2007; Tebano et al., 2008), 
and LTP (Fontinha et al., 2008) at the CA1 area of the hippocampus as well as at 
glutamatergic nerve ending where the release of glutamate is modulated by 
BDNF and adenosine (Canas et al., 2004; Pousinha et al., 2006; Assaife-Lopes et 
al., 2010). An interection between A2A and TrkB receptors has also been 
demonstrated at the neuromuscular junction (Pousinha et al., 2006), a single 
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nerve ending synapse model. The ability of BDNF to facilitate synaptic 
transmission on LTP (Diógenes et al., 2007) is dependent of the age of the 
animals (Diógenes et al., 2011) and this may be related to the degree of 
activation of adenosine A2A receptors by endogenous adenosine at different ages. 
In all cases the actions of BDNF are lost by blocking A2A receptors with 
selective antagonists. This requirement of A2A receptors acticatition to trigger a 
BDNF action was further confirmed by using A2A receptor knockout mice 
(Tebano et al., 2008). 
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2. AIM 
The main objective of the present work was to understand how BDNF could 
modulate GABA uptake at tripartite synapse level, namely to investigate the 
effect of BDNF on GABA transporter in the nerve terminal as well as in 
astrocytes from a functional and mechanistic point of view. Thus the following 
specific objectives were persued: 
1. to know the effect of BDNF on GABA transport mediated by GAT-1 in 
presynaptic nerve terminal and a possible modulation of this effect 
through activation of adenosien A2A receptors. 
2. to study the action of BDNF upon the GAT-1 and GAT-3 mediated 
uptake of GABA by astrocytes and the underlying mechanisms for this 
BDNF action. At this point I have studied the possible involvement of 
adenosine A2A receptors on BDNF effect.  
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3. TECHNIQUES 
The methods used in the presented thesis were the following: neurotransmiter 
uptake in nerve terminals (synaptosomes), neurotransmiter uptake in primary 
astrocyte cultures, molecular biology techniques (PCRs, plasmid manipulation, 
cell transfection), lentivirus production and cell transduction, biotinylation 
method and western blot analysis and affinity screening by Enzyme-Linked 
Immunosorbent Assay (ELISA). 
In this section, will be given an introduction to the techniques and preparations 
most used to help the comprehension of results.  
3.1.1. Neurotransmitter uptake from synaptosomes 
Synaptosomes are sealed presynaptic nerve terminals that were first isolated by 
Whittaker in 1958 (Whittaker, 1993) and identified as such by electron 
microscopy in 1962 (Gray and Whittaker, 1962). Synaptosomes contain all the 
components necessary to store, release and retain neurotransmitters. When 
oxygenated, synaptosomes maintain a plasma membrane of -60 to -70 mV in 
medium containing low concentration of K+ (Scott and Nicholls, 1980). The 
plasma membrane Ca2+-ATPase is primarily responsible for extruding Ca2+ from 
the synaptosomes (Snelling and Nicholls, 1985) and for maintaining the 
intarcellular calcium concentration  in polarized synaptosomes in the range 0.1-
0.3 µM (Richards et al., 1984). In addition, essentially all synaptosomes contain 
functioning mitochondria (Kauppinen and Nicholls, 1986) and unstimulated 
synaptosomes respire in the absence of glucose or in presence of a glycolytic 
inhibitor. Synaptosomal energy state is highly sensitive to “ischaemia-like” 
conditions, since inhibition of oxidative phosphorylation is followed by a drop of 
ATP and membrane potential (Kauppinen and Nicholls, 1986). Despite all 
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bioenergetic parameters that affect neurotransmission that can be measured by 
using synaptosomes, this biological preparation is quite usefull for quantifying 
release and uptake of neurotransmitters.  
In uptake experiments synaptosomes are incubated with fixed volume of medium 
before separation by filtration or centrifugation. This methodology is very usefull 
in the sense that uptake of neurotransmitters can be followed, as well as the 
bioenergetic parameters that affect neurotransmission, such as plasma and 
mitochondrial membrane potential, calcium fluxes, respiration, ATP/ADP ratios 
and translocation of receptors or transporter to plasma membrane.  
3.1.2. Primary astrocyte cell cultures 
The use of tissue culture, and its application to the problems of neurobiology, 
started more that 100 years ago, when Ross Granville Harrison observed the 
outhgrowth of fibers from fragments of frog and chick neural tube cultured in 
drops of clotted lymph or plasma (Harrison, 1907, 1910, 1912, 1914). The 
demonstration that tissue could survive and grow outside the body crated 
widespreade interest and soon were followed by those of other (for review, see 
Murray, 1965).  
About 45 years ago cell cultures began to gain a more prominant and important 
position in neurobiology: in 1969, two papers described the development of 
clonal lines of neuroblastoma cells obtained from a neural tumor (Augusti-Tocco 
and Sato, 1969; Schubert et al., 1969). When maintained in culture, these cells 
continued to proliferate but could be induced to stop division and acquire 
properties characteristic of differentiated neurons. On the other hand, two other 
papers described cultures of dissociated neurons from autonomic and sensory 
ganglia under conditions that led to the possibility of studing this type of cells as 
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individual living nerve cells (Bray, 1970; Yamada et al., 1970). The described 
types of cultures are referred to as cell lines and primary cultures, respectively.  
Primary cultures are prepared from cells taken directely from the animal. The 
cells divide or not, depending on their type, acquire differentiated characteristics 
of their tissue of origin and ultimately die. For a new culture is necessary to use 
other animal, in order to obtain new tissue from which new cells are dissociated. 
Same cells are still able to divide after being dissociated from the tissue while 
other never divide after dissociation. One exemple of cells that are able to divide 
in culture are glial cells, while neurons do not have this capacity.  
Cell culture is particulary valuable approach for studying glial development and 
function. It has been difficult to study the function of glia in situ because of the 
inherent heterogeneity of nervous tissue, hovewer it is relatively easy to obtain 
pure preparations of astrocytes, oligodendrocytes and Schwann cells, free of 
contaminating neurons. Astroglia precursor cells are particularly hard and gow 
readily in primary cultures. Usually cells are prepared from neonatal brain and 
divide relatively rapidly, forming a confluent monolayer of astroglia within a 
week or two.  The condition of culture preparation is chosen to preclude the 
survival of neurons but, in some cases, addicional steps are needed to remove 
other nonneuronal contaminants. Using this approach, it is possible to produce 
amounts of cells suitable for biochemical as well as morphological or 
physiological analysis (Banker and Goslin, 1998). 
3.1.3. Viral particles and infection of primary cell cultures 
Lentiviral vectors have been widely used in experimental gene therapy paradigms, 
because they are capable of transducing nondividing cells such as stem cells (e.g., 
hematopoetic stem cells) and terminally differentiated cells (e.g., neurons) 
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(Naldini et al., 1996a; Naldini et al., 1996b; Johansen et al., 2005).The most 
extensively used and best-characterized lentiviral vectors are based on the human 
immunodeficiency virus type 1 (HIV-1) genome, since the properties of HIV-1 
life cycle are consistent to the purpose of viral-mediated gene transfer, such as 
host cell attachment, receptor-mediated entry into host cells, viral mediated 
reverse transcription, and integration of the viral genome into the host-cell 
chromatin (Debyser, 2003; Kafri, 2004). Another feature of HIV-1 that makes it 
an ideal gene therapy vector and that is its ability to escape from cellular immune 
responses (Wodarz and Nowak, 1999). Following HIV-1 infection, neutralizing 
antibodies are rarely generated in vivo (Stebbing et al., 2003) and lentiviral 
vectors similarly integrate their genome into that of target cells without an 
inflammatory response (Kafri, 2004). Early generations of HIV-1-based vectors 
were unsuitable for gene therapy applications due to serious biosafety concerns. 
In recent years, however, the biosafety of lentivectors has been considerably 
improved by eliminating viral components and the main HIV transactivator, and 
by separating trans- and cis-acting viral components on different plasmids. 
Furthermore, the range of target cells has been vastly broadened by virus particle 
pseudotyping with the vesicular stomatitis virus glycoprotein (VSVG) envelope 
(for review, see Johansen et al., 2005). 
In lentiviral production a three-plasmid expression system is used to generate 
HIV-derived retroviral vector particles by transient transfection, as described for 
other vectors (Weinberg et al., 1991). Packaging cells are used as the viral factory 
where the three-plasmid are brought together to produce the vector particles. The 
packaging cells that are used to produce lentiviral vectors are 293T cells 
(ATCC#CRL-11268), a highly transfectable derivative of the 293 human fetal 
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kidney cell line, into which the temperature sensitive gene for simian virus 40 
(SV40) large T antigen has been inserted (Pear et al., 1993). 
The three plasmids involved in viral particles production are: a packaging 
construct, an envelope plasmid and a vector construct (transducing vector). In the 
work now presented the plasmid pCMV	R8.91, used as packaging construct, 
contains the human cytomegalovirus (hCMV) immediate early promoter and is 
defective for the production of the viral envelope as well as four accessory protein 
of HIV-1, Vif, Vpr, Vpu and Nef (Zufferey et al., 1997). Since cis-acting 
sequences were eliminated, this plasmid is not able of packaging, reverse 
transcription, and integration of transcripts derived from the packaging plasmid 
(Lever et al., 1989; Aldovini and Young, 1990).  To broaden the tropism of the 
vector, a second plasmid (pMD.G) that encodes a heterologous envelope protein 
is used (Naldini et al., 1996a). It was used a variant that encodes the G 
glycoprotein of vesicular stomatitis virus (VSV-G), which offers the additional 
advantage of high stability, allowing for particle concentration by 
ultracentrifugation (Burns et al., 1993). The third plasmid is the pHsCXW 
lentiviral transfer vector (Johansen et al., 2005), which is modified from a 
lentiviral transfer vector (pHR) originally generated by Naldini and collaboraters 
(Naldini et al., 1996b). The transducing vector contains cis-acting sequences of 
HIV required for packaging, reverse transcription, and integration, as well as 
unique restriction sites for the cloning of heterologous complementary DNAs 
(cDNAs). pHsCXW vector was obtained from pHR vector by including a 
polylinker and replacing the entire vector backbone with a pUC18 vector-derived 
backbone. These modifications allowed for easier cloning and higher DNA yields 
without compromising the fundamental ability of this vector system to transduce 
cells in vitro and in vivo (Johansen et al., 2005). 
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Figure 3.1.1. Schematic representation of the three-plasmid expression system used for 
generating viral particles by transient transfection. pHsCXW vector is the transducing plasmid, 
pCMV∆R8.91 is the packing vector and pMD.G is the envelope vector. 5'LTR: 5' long terminal 
repeat; Psi (Ψ): packaging signal; gag (truncated): structural protein; RRE: REV response element; 
SD: splice donor site; SA: splice acceptor site; CMV: cytomegalovirus promoter; MCS: multiple 
cloning site; T7: T7 promoter recognition site; WPRE: woodchuck postregulatory response element; 
3’LTR: 3’ long terminal repeat with partial U3 deletion that results in the self-inactivation of these 
vector; AmpR: β-lactamase expression cassette for ampicilin resistance; pUC18 ori: pUC18 vector-
derived replication origin; VSV-G: G glycoprotein of vesicular stomatitis virus; CMV: 
cytomegalovirus; REV: Regulator of Virion; TAT: transactivator (it is a regulatory gene which 
accelerates production of more HIV virus); POL: polymerase (Adapted from Naldini et al., 1996b; 
Zufferey et al., 1997; Johansen et al., 2005) 
CMV VSV-G polyA
CMV
GAG
POL
∆Ψ TAT
REV
RRE
polyA
Envelope plasmid: pMD.G
Packing plasmid: pCMVR8.91
Tranducing plasmid: pHsCXW
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3.1.4. Biotinylation 
The extraordinarily stable, non-covalent interaction between avidin and biotin is 
one of the most commonly exploited tools in chemistry and biology, being this 
technique known by biotinylation.  
Biotin, whose properties and structure are identical to Vitamin H, establish 
covalently bonds to protein lysine groups at temperatures low enough to inhibit 
endocytosis. The egg-white protein avidin has a high affinity for biotin (Boas, 
1927; Du Vigneaud et al., 1940; Gyorgy et al., 1940; Gyorgy et al., 1941), and 
hence biotinylated proteins can be efficiently purified from lysates with avidin 
conjugated to silica beads. Indeed, the interaction between biotin and avidin is one 
of the tightest known with a Kd of ~10−15 M (Green, 1975), and the robustness of 
this binding permits purification of biotinylated proteins from solutions 
containing denaturing agents such as SDS. Sulfo-NHS-biotin (N-
hydroxysulfosuccinimidobiotin) is a biotin derivative that is commonly used in 
neuronal receptor trafficking experiments as it contains a negatively charged 
sulphate group which confers membrane impermeablity, thus minimizing labeling 
of intracellular proteins; furthermore it has low cytotoxicity, being suitable for 
experiments lasting many hours. 
Although biotinylation is a biochemical technique that does not permit 
visualization of receptor location, it has many advantages over techniques that 
label surface receptors with specific antibodies. It is particularly useful if 
antibodies to the protein in question are not suitable for microscopy, or are raised 
to intracellular and therefore inaccessible domains. Biotinylation also affords the 
luxury of being able to study the trafficking of multiple different 
receptors/membrane proteins within the same experiment. During biotinylation 
experiments, the receptors on millions of cells are assayed simultaneously, with 
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greater quantitative sensitivity than that obtained while using immunofluoresence 
techniques, and so subtle differences in endocytosis and trafficking rates can be 
evaluated (for review, see Arancibia-Carcamo et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Western Blot
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Figure 3.1.2. Cell surface biotinylation (Adapted from Elschenbroich et al., 2010) 
 
3.1.5. ELISA (Enzyme-Linked Immunosorbant Assay) 
The ELISA was developed in 1970 by Eva Engvall and Peter Perlmann (Engvall 
and Perlmann, 1971). The purpose of an ELISA assay is to determine if a 
particular protein is present in a sample and if so, how much. There are two main 
variations on this method: it is possible to determinate how much antibody is in a 
sample, or to determinate how much protein is bound by an antibody. The 
distinction is whether trying to quantify an antibody or some other protein.  
In the simplest system, bound antigen is probed with antibodies which carry 
covalently attached enzyme molecules. Antibody binding immobilizes enzyme in 
the vicinity of the bound antigen, allowing detection of the antigen. Variations 
include competitive ELISA in which sample antigen is used to titrate the antibody 
from bound antigen. In this system, comparison of signal with signals from 
known antigen standards allows very accurate quantitation. In sandwich (capture) 
ELISAs, the antibody is bound to a surface, and used to capture the antigen for 
detection by a second antibody. Sandwich ELISAs are extremely specific, 
because the antigen must react with 2 antibodies to be detected. ELISA signals 
may be chromogenic and interpreted by eye or spectrophotometer, or luminogenic 
and detected by a luminometer. Typically, ELISA's are run in 96 well plates. 
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Figure 3.1.3. The variations of ELISA (Enzyme Linked Immunosorbent Assay). Top: Basic 
ELISA, in which antigen is bound to a surface and probed with enzyme linked antibody, providing 
semi-quantitative information. Middle: Competitive ELISA. Purified antigen is bound to the 
surface. Probing is carried out in the presence of samples or dilutions of free antigen (standards). 
The free antigen competes with the bound antigen, reducing the amount of antibody bound. 
Comparison between samples and standards yields quantitative information. Bottom: Sandwich 
ELISA, using one antibody to capture the antigen and another to detect it, resulting in increased 
specificity (Adapted from http://www.nationaldiagnostics.com/article_info.php/articles_id/90). 
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4. METHODS AND MATERIAL  
4.1. Biological sample preparation 
4.1.1. Synaptosomes 
The synaptosomal fraction from Wistar rat hippocampus (3-4 weeks old) was 
prepared as routinely in our laboratory (Pinto-Duarte et al., 2005), according to 
the European guidelines (86/609/EEC). Briefly, the animals were anaesthetized 
with halothane before decapitation, the brain was quickly removed, the 
hippocampi were dissected out and added to 5 ml of a chilled sucrose solution (in 
mM: 320 sucrose, 1 EDTA, 10 HEPES, 1 mg/ml BSA, pH 7.40); after 
homogenization at 4ºC, the volume was completed to 15 ml with ice-cold sucrose 
solution. After a first centrifugation at 3000 x g for 10 minutes (Heraeus sepatech 
– Biofuge 28RS centrifuge, refrigerated at 4ºC), the supernatant was collected, 
centrifuged at 14000 x g for 12 minutes and the pellet resuspended in 3 ml Percoll 
solution, which contained Percoll 45% (v/v) in KHR solution (in mM: 140 NaCl, 
1 EDTA, 10 HEPES, 5 KCl and 5 glucose, pH 7.40), adjusted to pH 7.4 with 
NaOH. The mixture was centrifuged again at 14000 x g for 2 minutes and the top 
layer, which corresponds to the synaptosomal fraction, was removed, washed with 
2 ml KHR solution and centrifuged again at 14000 x g for 2 minutes.  
The synaptosomal fraction was resuspended in 1 ml of chilled Krebs-HEPES 
solution (in mM: 10 glucose, 125 NaCl, 3 KCl, 1.2 MgSO4, 1 NaH2PO4, 1.5 
CaCl2, 0.1 A.O.A.A. and 10 HEPES, pH 7.40) and kept at 4ºC until use. The 
synaptosomal protein concentration was assayed according to the Bradford 
method (Bradford, 1976) using bovine serum albumin as standard. 
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4.1.2. Rat astrocytes cell cultures 
Cultures of astrocytes from Wistar rat cerebral cortex were prepared as previous 
reported (Biber et al., 1997). In brief, rat brains were dissected out of newborn 
Wistar rats pups (0–2 days old). After the brains were dissected, the olfactory 
bulbs, hippocampal formations, basal ganglia and meninges were carefully 
removed in cold PBS solution (in mM: 140 NaCl, 2.7 KCl, 1.5 KH2PO4 and 8.1 
NaHPO4, pH 7.40).  Cortex tissue was dissociated gently by trituration in 4.5 g/l 
glucose Dulbecco’s Modified Eagles Medium (DMEM, Gibco, Paisley, UK) and 
filtered through meshes of 230 µm and centrifuged at 200 g for 10 minutes (at 
room temperature). The pellet was resuspended in 4.5 g/l glucose DMEM 
medium and passed through meshes of 70 µm (BD Falcon, Erembodegem, 
Belgium) and centrifuged at 200 g for 10 minutes (at room temperature). Cells 
were seeded into 24-well plates for uptake experiments, into 6-well plates for 
biotinylation experiments and 96-well plates for ELISA experiments. Cultures 
were maintained for 3 weeks in 4.5 g/l glucose DMEM medium supplemented 
with 10% fetal bovine serum (FBS, Gibco Paisley, UK) and 0.01% 
antibiotic/antimycotic (Sigma, Steinheim, Germany) in a humidified atmosphere 
(5% CO2) at 37°C, however during the first 2 days cells were maintained in 4.5 
g/l glucose DMEM medium containing 20% FBS and 0.01% 
antibiotic/antimycotic.  
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4.2. Methods 
4.2.1. GABA uptake mediated by GABA transporters in rat synaptosomes 
The protocol for [3H]GABA uptake was adapted from Santos and collaborators 
(Santos et al., 1990). Briefly, the synaptosomal suspension (0.5 mg protein ml-1) 
in Krebs-HEPES solution was preincubated at 37ºC for 20-35 minutes in a total 
volume of 300 µl, in the presence or absence of testing drugs, and the transport 
was initiated by addition of 5 µM [3H]GABA (specific activity 0.133 Ci/mmol), 
unless otherwise specified. Transport was terminated after 40 seconds by the 
addition of 5 ml ice-cold Krebs-HEPES solution followed by low-pressure 
filtration through 1.2 µm filters (Millipore, Glass Fibre Prefilters) and a second 
wash with 10 ml of the same solution. The 40 seconds incubation time was 
chosen since we observed a linear correlation between the uptake of GABA vs. 
incubation times ranging from 0 to 80 s (correlation coeficent = 0.95). The filters 
were analysed by liquid scintillation counting for determination of tritium 
retained by synaptosomes after addition of 5 ml of scintillation cocktail 
(OptiPhase “HiSafe” 2, Perkin-Elmer, Foster City, CA, USA). GAT-1 mediated 
GABA uptake was calculated as the difference between the total radioactivity 
retained in the filters and the non GAT-1 mediated component of [3H]GABA 
uptake, which was determined by preincubation with SKF89976a (20 µM), an 
inhibitor of GAT-1 transporter (Borden et al., 1994a).  
BDNF was added to the synaptosomes 5 min before addition of [3H]GABA and 
the effect of BDNF was calculated taking as 100% the uptake of GABA in the 
absence of BDNF in the same experiments and under the same experimental 
conditions. Whenever the influence of any drug over the effect of BDNF was 
tested, that drug was incubated with the synaptosomes for at least 15 min before 
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addition of BDNF; the effect of BDNF in the presence of these drugs was 
calculated taking as 100% the uptake of GABA in the absence of BDNF but in the 
presence of the same drugs. Whenever removal of endogenous adenosine was 
required, adenosine deaminase (ADA, 1 U/ml) was added 30 min before BDNF. 
4.2.2. GABA uptake mediated by GABA transporters in rat astrocytes 
For determination of GABA uptake, astrocytes were preincubated for 3 h at 37ºC 
in serum-free 1 g/l glucose DMEM (Gibco, Paisley, UK). Following 
preincubation, cells were rinsed one time in 1 g/l glucose DMEM free serum and 
allowed to equilibrate for 10 min in this medium.  Buffer was then exchanged 
with control DMEM or drug containing DMEM. The transport was initiated by 
addition of 30 µM [3H]GABA (specific activity 0.141 Ci/mmol) (PerkenElmer, 
Boston, MA, USA) in a transport buffer (KHR) composed of (in mM): 137 NaCl 
137, 5.4 KCl, 1.8 CaCl2·2H2O, 1.2 MgSO4 and 10 HEPES, pH adjusted with 
NaOH to 7.40. Transport was stopped 1 min after [3H]GABA addition by rapidly 
washing the cells twice with ice-cold stop buffer (in mM: 137 NaCl and 10 
HEPES, pH adjusted with Tris-base to 7.40) followed by solubilization with 250 
µl of lyses buffer (in mM: 100 NaOH and 0.1% SDS) at 37ºC for 1 hour. The 
amount of [3H]GABA taken up by astrocytes was quantified by liquid scintillation 
counting. GAT-1 and GAT-3-mediated GABA uptake was taken as the difference 
between the [3H]GABA uptake in the absence and in the presence of the GAT-1 
blocker, SKF 89976a (20 µM) and the GAT-3 blocker, SNAP 5114 (20 µM), 
respectively.  
BDNF was added to astrocytes 10 min before addition of [3H]GABA and the 
effect of BDNF was calculated taking as 100% the uptake of GABA in the 
absence of BDNF in the same experiments and under the same experimental 
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conditions. Whenever the influence of any drug over the effect of BDNF was 
tested, that drug was incubated with the cells for 20 min before addition of 
BDNF; the effect of BDNF in the presence of these drugs was calculated taking as 
100% the uptake of GABA in the absence of BDNF but in the presence of the 
same drugs. GAT-1 and GAT-3 blockers were added to astrocytes at the same 
time that other used drugs.  
Statistical analyses of the uptake data were performed using GraphPad (San 
Diego, CA, USA) Prism software. Two-sample comparisons were made using t 
tests; multiple comparisons were made using one-way analysis of variances 
(ANOVAs) followed by Bonferroni correction post-test. 
4.2.3. Plasmid construction 
To generate HA tagged GAT-1 the sequence of YPYDVPDYA (HA epitope) was 
inserted in the extracellular loop 2 (EL2) of rat GAT-1-pRc/CMV as previously 
described (Sorkina et al., 2006).  The HA tag insertion was made using a 
Stratagene (La Jolla, CA, USA) Quick-change mutagenesis kit according to the 
manufacture’s protocol.  
First, it were generated four different HA tagged GAT-1 that differ in the location 
of the HA tag insertion in EL2 of the transporter. Thus four forward and four 
reverse primers were design and named has HA1, HA2, HA3 and HA4.  The 
designed primers for the several HA tags insertion in EL2 of rat GAT-1 were: 
HA1 - Forward - CTCCAACTATAGCTACCCCTACGACGTCCCCGATTACG 
CCTCACTGGTCAACACCAC and HA1-Reverse-GTGGTGTTGACCAGTGA 
GGCGTAATCGGGGACGTCGTAGGGGTAGCTATAGTTGGAG; HA2-
Forward- CTGGTCAACACCACCTACCCCTACGACGTCCCCGATTACGC 
CTCACTCAACATGACCAGTGCC and HA2-Reverse – GGCACTCATGTTGA 
Modulation of GAT-1 transporters by BDNF and A2A receptors 
 
 62
GTGAGGCGTAATCGGGGACGTCGTAGGGTAGGTGGTGTTGACCAG; 
HA3 - Forward - CCACCAACATGACCTACCCCTACGACGTCCCCGATTAC 
GCCAGTCTCGTGGTGGAATTC and HA3-Reverse-GAATTCCACCACCAG 
ACTGGCGTAATCGGGGACGTCGTAGGGGTAGGTCATGTTGGTGG; HA4 
–Forward- CTGGTCAACACCTACCCCTACGACGTCCCCGATTACGCCTCA 
CTCAACATGACCAGTGCC and HA4-Reverse-GGCACTGGTCATGTTGAGT 
GAGGCGTAATCGGGGACGTCGTAGGGGTAGGTGGTGTTGACCAG. The 
HA tag insertion was verified by automatic dideoxynucleotide sequencing.  
After kinetic analysis of all HAs-rGAT-1 in HEK293T cells (see 3.3.8. Kinetic 
analysis of rGAT-1 and HA-rGAT-1 in HEK cells), the construct with more 
similar kinectic characteristics to rGAT-1 wild type, namely HA2, was insert on a 
lentiviral transfer vector. Thus, to insert GAT-1 and HA tagged GAT-1 (the 
previously named HA2) on the lentiviral transfer vector pHsCXW a forward 
primer (GCATAAGCTTCTAGACATGGCGACTGA CAACAGC) containing a 
XbaI digestion site and a reverse primer (CAACTAGAAGGCACAGTCGAG) 
for a region of pRc/CMV vector localized after the XbaI restriction site were used 
to amplify the rat GAT-1 sequence by PCR using Phusion polymerase. Both DNA 
fragments, GAT-1 and HA-GAT-1, were cloned into pHsCXW vector, using 
XbaI restriction enzyme. 
4.2.4. Lentivirus production and transduction 
Lentiviral vectors were produced according to procedures modified from (Naldini 
et al., 1996b). HEK293T packaging cells (ATCC number CRL-11268) were 
plated on poly-lysine-coated 175 cm2 flaks and transiently triple transfected with 
the following: (1) 18 µg of a packaging plasmid encoding viral structure proteins 
(pBR∆8.91) (Zufferey et al., 1997); (2) 12 µg of an envelope plasmid encoding 
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the envelope protein VSV-G (pMD.G) (Naldini et al., 1996a); and (3) 18 µg of 
the transfer plasmid containing the gene of interest (pHsCXW-rGAT-1 or 
pHsCXW-HA-rGAT-1). Transfection was performed in DMEM (Gibco) 
supplemented with 10% FBS (Invitrogen) using calcium phosphate precipitation. 
Medium was replaced with fresh medium after 5 h. Approximately 48 and 72 h 
after transfection, media containing lentivirus was collected, centrifuged at 900 x 
g for 5 min to remove cellular debris, filtered through a 0.45 µm filter, and 
concentrated by ultracentrifugation at 50,000 x g for 1.5 h at 4°C. The virus-
containing pellet was resuspended in MEM (Sigma) at 1/280 of the original 
volume and stored in aliquots at –80°C. The astrocyte cultures were incubated 
with concentrated lentivirus on days 14-21 in vitro and experiments were 
performed 6–8 d after infection.   
4.2.5. HEK293 cell culturing and transfection 
HEK293 cells (ATCC, number CRL-1573) were grown in DMEM supplemented 
with 10% FBS and gentamicin (10 g/ml) at 37 °C in a humidified incubator with 
5% CO2. Transfection was carried out using Lipofectamine 2000 (Invitrogen, 
Carlsbed, CA, USA). For uptake experiments, 1 g plasmid encoding the cDNA 
of interest was used for transient transfection of cells in a 75 cm2 culture flask. 
Cells were assayed 48–72 h after transfection. 
4.2.6. Kinetic analysis of rGAT-1 and HA-rGAT-1 in HEK cells 
The cells were grown in 24-well plates for 2d and tranfected with rGAT-1 or HA-
rGAT-1 using Lipofectamine 2000. Cells were assayed in the transport buffer 
(KRH; in mM: 137 NaCl, 5.4 KCl, 1.8 CaCl2, 1.2 MgSO4, 10 HEPES, pH 
adjusted with NaOH to 7.40.). Assays included 8.62 nM [3H]GABA and 
increasing concentrations of unlabeled GABA (1, 2.5, 4, 5, 7.5, 15, 25 and 50 
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µM). Nonspecific [3H]GABA accumulation was determined in the presence of 20 
µM SKF89976a. After 1 min of incubation with GABA containing buffer at RT, 
uptake was terminated by quickly washing the cells two times with 1 ml of ice-
cold stop solution (in mM: 137 NaCl and 10 HEPES, pH 7.4). Cells were then 
solubilized in 0.250 ml of 1% SDS for 60 min with gentle shaking. Accumulated 
[3H]GABA was determined by liquid scintillation counting. Km and Vmax values 
for [3H]GABA uptake were calculated with nonlinear regression fitting using 
GraphPad (San Diego, CA, USA) Prism software.  
4.2.7. Biotinylation experiments 
Astrocytes were grown in 6 well plates and transduced with rGAT-1 lentivirus on 
days 13-15 in vitro and experiments were performed 6–8 d after transduction. 
After a starvation period of 3 h cells were treated with BDNF for 10 min. The 
cells were rinsed twice with 4°C phosphate-buffered saline (PBS)/ Ca2+/Mg2+ 
(138 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 9.6mM Na2HPO4, 1 mM MgCl2, 
0.1mM CaCl2, pH 7.3). The cells were next incubated with a solution containing 
1.2 mg/ml sulfo-NHS biotin (Pierce, Rockford, IL, USA) in PBS/Ca2+/Mg2+ for 
40 min at 4°C. The biotinylation solution was removed by two washes in 
PBS/Ca2+/Mg2+ plus 100 mM glycine. The cells were rinsed twice with 4°C 
PBS/Ca2+/Mg2+. The cells were solubilised with lysis buffer (25 mM Tris-base, 
pH 7.5, 150 mM NaCl, 5 mM N-Ethylmaleimide (NEM), 1 mM EDTA, 1% 
Triton X-100, 0.2 mM phenylmethanesulfonyl fluoride (PMSF) and protease 
inhibitor cocktail from Roche (Mannheim, Germany)) at 4°C and incubated with 
rotation for 20 min at 4ºC. The cell lysates were centrifuged at 16,000 x g at 4°C 
for 15 min. The supernatant fractions (300 µg of protein) were incubated with 
Avidin agarose resine (Pierce, Rockford, IL, USA) at room temperature (RT) for 
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60 min. The beads were washed four times with lysis buffer, and adsorbed 
proteins were eluted with 5x SDS sample buffer (50 mM Tris- Cl, pH 6.8, 2% 
SDS, 100 mM Dithiothreitol (DTT), 0.1% bromophenol blue, 10% glycerol) at 
37ºC for 30 min. The supernatant was collected (surface membrane expression) 
for western blot analysis. Astrocytes lysates were also denaturated with 5x SDS 
sample buffer and an equal quantity (30 µg) were used for western blot analysis. 
Protein determination was made using Bio-Rad Dc Protein Assay. 
4.2.8. Western blot assays 
After denaturation (by SDS sample buffer at 37ºC for 30 minutes), both the 
extracts from biotinylated fractions and the astrocytes lysates were run on a 7.5% 
SDS-PAGE gel. Protein was transferred to a PDVF membrane (Millipore, 
Bedford, MA, USA) by electroblotting and blocked for 1 h at room temperature 
with 5% non-fat milk in PBS with 0.05% Tween-20 (PBS-T). Incubations with 
primary antibodies were performed overnight at 4ºC, all of them diluted in 3% 
BSA in PBS-T and 0.02% sodium azide. HRP-coupled secondary antibodies were 
diluted in blocking buffer and incubated for 1 h at RT. Detection of proteins was 
made with ECL plus Western blotting detection (Amersham Biosciences, 
Buckinghamshire, UK). 
4.2.9. Affinity Screening by Enzyme-Linked Immunosorbent Assay 
(ELISA) 
For ELISA experiments astrocytes were grown in 96 well plates coated with poli-
ornythn and transduced with HA-rGAT-1 lentivirus on days 14-21 in vitro, in 
order to perform the experiment 6–8 d after transduction. Before the experiment, 
astrocytes were treated or not with different concentrations of BDNF for 10 
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minutes, as indicated. After BDNF incubation, cells were fixed in 4% PFA in 
phosphate-buffered saline/Ca2+/Mg2+ (138 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 9.6mM Na2HPO4, 1 mM MgCl2, 0.1mM CaCl2, pH 7.3) for 20 minutes 
on ice, washed twice in PBS/Ca2+/Mg2+, blocked in 5% goat serum in 
PBS/Ca2+/Mg2+ for 30 minutes and incubated with HA.11 antibody (1:1000) in 
5% goat serum/PBS/Ca2+/Mg2+ for 60 minutes. Following 4 washes in 
PBS/Ca2+/Mg2+, cells were then incubated with HRP-conjugated goat anti-mouse 
antibody (1:1000; Pierce, Rockford, IL, USA) for 30 minutes and subsequently 
washed 4 additional times in PBS/Ca2+/Mg2+. The HRP activity was detected and 
quantified instantaneously by chemiluminescence using Supersignal ELISA femto 
maximum sensitivity substrate (Pierce) and a Wallac Victor 2 luminescence 
counter (PerkinElmer Life Science, Boston, MA, USA). 
4.2.10. Reagents 
GABA was purchased from Sigma (St. Louis, USA) and [3H]GABA (4-amino-n-
[2,3-3H]butyric acid, specific activity 92.0 Ci/mmol) from PerkenElmer Life 
Sciences (Boston, MA, USA). Stock solutions of BDNF (kindly supplied by 
Regeneron Pharmaceuticals, Tarrytown, New York) were in phosphate-buffer 
saline (PBS) at a final concentration of 1 mg/ml. Adenosine deaminase (E.C. 
3.5.4.4, 200 U/mg in 50% glycerol (v/v), 10 mM potassium phosphate) was 
purchase from Roche. CGS21680 (4-[2-[[6-amino-9-(N-ethyl-b-D-ribofuranu-
ronamidosyl)-9H-purinyl]amino]ethyl]benzene-propanoic acid hydrochloride), 
SCH58261 (2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazo-
lo[1,5-c]pyrimidin-5-amine), U73122 (1-[6-[[(17b)-3-methoxyestra-1,3,5(10)-
trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione), SKF 89976A hydrochloride (1-
(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acidhydro-chloride), SNAP5114 
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(1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-(S)-3-piperid inecarboxylic acid) 
were purchsed from Tocris (Bristol, UK). K252a was acquired Calbiochem 
(Darmstadt, Germany). LY 294002 (2-(4-Morpholinyl)-8-phenyl-1(4H)-
benzopyran-4-one) and U0126 (1,4-Diamino-2,3-dicyano-1,4-bis(2-
aminophenylthio)butadiene) were acquired from Ascent (Weston-Super-Mare, 
UK). H-89 dihydrochloride hydrate (N-[2-(p-bromocinnamylamino) ethyl]-5 
isoqui-nolinesulfonamide dihydrochloride), forskolin, dynasore hydrate and 
monensin sodium salt were obtained from Sigma.  
The following stock solutions were prepared in dimethylsulfoxide: CGS 21680 (5 
mM), SCH 58261 (5 mM), U73122 (5 mM), H-89 (5 mM), forskolin (5 mM), 
K252a (1 mM), LY 294002 (10 mM), U0126 (10 mM). SKF 89976A (10 mM) 
and SNAP 5114 (10 mM) were prepared in water. All aliquots were kept frozen at 
-20ºC until used; appropriate dilutions in incubation buffer were daily prepared.  
Antibodies were purchase from the following sources: rabbit polyclonal antibody 
to GAT-1 (AB1570W) from Millipore (Bedford, MA, USA); rabbit anti-phospho-
Trk (pTyr-490), rabbit anti-phospho-Akt, rabbit anti-PLC1, rabbit anti-phospho-
p44/p42 MAPK and rabbit anti-p44/p42 MAPK from Cell Signaling (Boston, 
MA, USA); mouse monoclonal antibody to Akt1 and mouse monoclonal antibody 
to PLC1 from Santa Cruz (Santa Cruz, CA, USA); mouse monoclonal antibody 
HA11 from Covance (Princeton, NJ, USA); rabbit polyclonal antibody to beta-
actin from Abcam (Cambridge, MA, USA); mouse IgG1 antibody to TrkB from 
BD Bioscience (San José, CA, USA); goat anti-mouse antibody conjugated with 
HRP from Pierce (Rockford, IL, USA); goat anti-mouse antibody conjugated with 
HRP from Santa Cruz (Santa Cruz, CA, USA); goat anti-rabbit antibody 
conjugated with HRP from Santa Cruz (Santa Cruz, CA, USA). 
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5. RESULTS 
5.1. BDNF induces modulation of GABA transport into nerve terminals 
5.1.1. Rationale  
As detailed in the introduction GABA activity at synapses is terminated by rapid 
reuptake through specific high-affinity Na+/Cl− dependent transporters (GATs), 
which are located on the plasma membrane of neurons and astrocytes, in close 
apposition to the synapse. The activity of GATs regulates GABA levels at 
synapses and therefore influences neuronal excitability. The most copiously 
expressed GABA transporter in the brain is GAT-1 (see Conti et al., 2004) and it 
is regulated by several signalling cascades that include kinases and phosphatases 
(Quick et al., 2004) as well as direct interaction with synaptic proteins (Quick, 
2006). The number of functional GAT-1 in cultured neurons is increased by direct 
tyrosine phosphorylation, an action mimicked by BDNF making it a plausible 
candidate as the physiological trigger of the tyrosine phosphorylation signalling 
cascade (Law et al., 2000). BDNF also has fast actions on synapses that occur in a 
time scale of less than 1 h and lead to facilitation of synaptic transmission (Kang 
and Schuman, 1995a; Diógenes et al., 2004). However, some synaptic BDNF 
actions result from a local and very fast action at synapses; indeed, this 
neurotrophin is able to facilitate glutamate release from isolated nerve endings 
(synaptosomes) (Sala et al., 1998; Canas et al., 2004; Pereira et al., 2006; Assaife-
Lopes et al., 2010), which therefore lack the somatic machinery for modulation at 
the gene transcription level. Interestingly, BDNF inhibits carrier mediated release 
of GABA from hippocampal synaptosomes (Canas et al., 2004), suggesting an 
inhibitory action upon GABA transporters. Since GABA transporters operating at 
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presynaptic level are physiologically designed to remove GABA from the 
synapses, it was decided to first evaluated the influence of BDNF on GAT-1-
mediated GABA uptake by isolated nerve terminals. The involment of adenosine 
A2A receptor upon BDNF effect was also studied. 
5.1.2. Determination of the Km and Vmax for GAT-1 transporter in rat 
hippocampal synaptosomes 
An initial experiment was performed to determine the Km value of GAT-1 for 
GABA in nerve terminals. The concentrations of GABA ranged from 0.3 to 10 
µM and the Km obtained was 5.05 µM (95% confidence intervals from 3.04 to 
7.04 µM, Figure 5.1.1), a value similar to that already reported by other authors 
(Wood and Sidhu, 1986). The remaining experiments were therefore performed 
with 5 µM GABA, since the use of this concentration of GABA will allow to 
observe enhancement or inhibition of transport in presence of tested drugs. On the 
other hand, it was also observed that the uptake of GABA was almost completely 
blocked by the selective GAT-1 inhibitor, SKF89976a (20 µM), an evidence that 
GAT-1 transporter is by far the predominant GABA transporter in the 
synaptosomal preparation (Figure 5.1.2). This indicates that in the present 
experimental conditions, any contamination with astrocytic membranes, which 
predominantly possess GAT-3 (Schousboe et al., 2004), does not appreciably 
contribute to GABA transport values and that the observed effects are indeed 
mediated by GAT-1 transporter located presynaptically.  
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Figure 5.1.1. Saturation analysis of GAT-1 mediated GABA transport. Data shown in the graph 
was obtained from one experiment. The averaged Km (Michaelis constant) and Vmax (maximal 
velocity) values are shown in the graph.  
 
 
 
 
 
 
 
Figure 5.1.2. SKF89976a, a high affinity antagonist of GAT-1, blocks a majority of GABA 
uptake in nerve terminals.  Drug concentration (in µM) is shown below the abscissa. 
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5.1.3. BDNF decreases GABA uptake from rat hippocampal synaptosomes 
Next it was evaluated the effect of BDNF on GABA transporter mediated by 
GAT-1 in synaptosomes. As shown in Figure 5.1.3.A, BDNF (10 - 200 ng/ml) 
caused a concentration dependent decrease in GAT-1 mediated GABA uptake, 
maximum effects being already observed with 100 ng/ml. An intermediate 
concentration of BDNF (30 ng/ml) was used in the remaining experiments. The 
effect of BDNF was very fast since a full effect could be observed after 1 min 
incubation and it was kept constant up to 20 min incubation (Figure 5.1.3.B). In 
the remaining experiments, a 5 min incubation period with BDNF was used.  
 
 
 
 
 
 
 
 
Figure 5.1.3. Brain-derived neurotrophic factor inhibits GABA uptake in hippocampal 
synaptosomes. A. concentration-response curve for the effect of BDNF (n=6); B. time-course curve 
of BDNF effect (30 ng/ml, n=4). In each experiment, the effect of BDNF in the absence and in the 
presence of the enzyme inhibitors was always tested using the same synaptosomal batch. BDNF was 
incubated with the synaptosomes for 5 min, except for the time-course experiments (B.), where the 
BDNF incubation times are indicated below each filled column. The ordinates represent [3H]GABA 
uptake as percentage of the control value in the same experiments, which was taken as 100%. The 
results are mean ± S.E.M.;**p<0.01, as compared with absence of BDNF in the same conditions. 
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5.1.4. BDNF effect upon GAT-1 is mediated through activation of TrkB 
receptor  
BDNF operates through the high-affinity receptor tyrosine kinase, TrkB, and the 
p75 receptor, which lacks catalytic activity (see e.g. Chao, 2003). Although 
different TrkB receptor isoforms are generated by alternative splicing, namely one 
full-length form of TrkB (TrkB-fl) (Berkemeier et al., 1991; Klein et al., 1991; 
Middlemas et al., 1991; Soppet et al., 1991; Squinto et al., 1991) and three 
truncated TrkB (TrkB-t1, TrkB-t2 and TrkB-t-Shr) isoforms with the same 
extracellular and transmembrane domains as TrkB-fl but with “truncated” 
intracellular domains lacking the kinase domain (see chapter 1.4.1) (Klein et al., 
1990; Middlemas et al., 1991; Shelton et al., 1995; Stoilov et al., 2002), neurons 
mainly express the TrkB-fl receptor and this isoform has been described as 
responsible for BDNF fast actions that lead to facilitation of synaptic transmission 
(Kang and Schuman, 1995b; Diógenes et al., 2004; Pousinha et al., 2006; 
Diogenes et al., 2007; Fontinha et al., 2008; Assaife-Lopes et al., 2010), 
facilitation of end plate potential (Pousinha et al., 2006) and log-term potentiation 
(LTP) (Fontinha et al., 2008). Thus, the described inhibitory effect of BDNF can 
be attributed to activation of TrkB-fl. To test this hypothesis the tyrosine kinase 
inhibitor, K252a (100 nM, Tapley et al., 1992), was used simultaneously with 
BDNF. K252a by itself was devoid of effect upon GABA uptake, but prevented 
the inhibitory action of BDNF (30 ng/ml) on GABA uptake (Figure 5.1.4.A). 
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Figure 5.1.4. Brain-derived neurotrophic factor effect on GABA transport is mediated by 
TrkB receptor, being a PLCγ-dependent mechanism.  A. the blockade of the effect of BDNF by 
the inhibitor of tyrosine kinase autophosphorylation, K252a (n=3); B. the ability of the PLC 
inhibitor, U73122 (n=5) to prevent the effect of BDNF. In each experiment, the effect of BDNF in 
the absence and in the presence of the inhibitors was always tested using the same synaptosomal 
batch. Synaptosomes were incubated with BDNF for 5 min. All other drugs were added 15 min 
before BDNF as indicated below each bar in A and B. The ordinates represent [3H]GABA uptake as 
percentage of the control value in the same experiments, which was taken as 100%. The results are 
mean ± S.E.M.; *p < 0.05, as compared with absence of BDNF in the same conditions. 
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BDNF, through TrkB receptors, induces activation of different signalling 
pathways, namely ERK, phosphatidylinositol 3-kinase (PI3-K) and phospholipase 
Cγ (PLC-γ) (Chao, 2003; Huang and Reichardt, 2003), the last one being 
frequently involved in synaptic actions of BDNF (eg Pousinha et al., 2006). In rat 
hippocampal synaptosomes, BDNF induces PLC-γ activation but does not affect 
ERK or PI3-K/Akt signaling pathways (Pereira et al., 2006). Therefore, we only 
evaluated the requirement of the PLC-γ signalling pathway. The synaptosomes 
were previously incubated for 20 min with the PLC inhibitor, U73122, which was 
used at a supramaximal concentration (3 mM, Bleasdale et al., 1990; Smith et al., 
1990). As shown in Figure 5.1.3.B, U73122 (3 µM) fully prevented the inhibitory 
action of BDNF (30 ng/ml) upon GABA uptake by the synaptosomes, indicating 
that this effect of BDNF requires PLC activity.  
5.1.5. Endogenous activation of A2A receptors is not required for the 
inhibitory action of BDNF upon GABA uptake 
It was previously observed that blockade of adenosine A2A receptors fully 
prevents the facilitatory action of BDNF upon synaptic transmission and plasticity 
at the hippocampus (Diogenes et al., 2004; Diogenes et al., 2007; Fontinha et al., 
2008) as well as at the neuromuscular junction (Pousinha et al., 2006). Therefore, 
the influence of A2A receptors upon the inhibitory action of BDNF on GABA 
transport was evaluated. The A2A receptor antagonist, SCH 58261, at a 
concentration (50 nM) nearly 70 times its Ki value for A2A receptors  (Zocchi et 
al., 1996a) and below its Ki value for other rat adenosine receptor subtypes, was 
incubated with the synaptosomes for 15 min before addition of BDNF (30 ng/ml) 
and the amount of GABA transported under these conditions was taken as 100%.  
As illustrated in Figure 5.1.5A, the inhibition of GABA uptake induced by BDNF 
(30 ng/ml) in the presence of SCH 58261 was not significantly different (p>0.05) 
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from that observed with the same synaptosomal batch in the absence of SCH 
58261. This indicates that tonic activation of adenosine A2A receptors is not 
required to trigger a BDNF effect upon GABA uptake. A2A receptor activation 
with a selective agonist, CGS 21680 (30 nM, Jarvis et al., 1989) also did not 
significantly (p>0.05) influence the inhibitory effect of BDNF upon GABA 
transport (Figure 5.1.5A). 
By itself SCH 58261 (50 nM) inhibited GAT-1 mediated GABA uptake by 26 ± 
4.5% (n=5, p<0.05), suggesting that the adenosine released by synaptosomes is 
tonically activating A2A receptors to enhance GAT-1 mediated GABA transport. It 
is therefore possible that membrane A2A receptors were already occupied with the 
endogenous ligand, which would occlude any further action of an exogenously 
added agonist, such as CGS 21680. To evaluate the influence of A2A receptor 
activation in the absence of endogenous adenosine, synaptosomes were incubated 
with adenosine deaminase (ADA, 1 U/ml, added 30 min before GABA uptake 
assay) to inactivate external adenosine, and the effect of BDNF in the absence or 
presence of the A2A receptor agonist was compared. As illustrated in Figure 
5.1.5.B., activation of A2A receptors with GCS 21680 (30 nM) in an external 
adenosine depleted background caused a significant (p<0.05) potentiation of the 
inhibitory effect of BDNF (30 ng/ml) upon of GAT-1 mediated GABA transport. 
This potentiation of the BDNF action by the adenosine A2A receptor agonist was 
prevented by the selective A2A receptor antagonist, SCH 58261 (50 nM), since in 
the simultaneous presence of the A2A receptor agonist and antagonist BDNF (30 
ng/ml) inhibited GABA uptake by a similar magnitude as in the absence of any 
A2A receptor ligand (Figure 5.1.5).  
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Figure 5.1.5. Modulation of the effect of BDNF upon synaptosomal GABA uptake by 
adenosine A2A receptors. The A2A receptor ligands were added to the synaptosomes either in the 
absence (A, n=6) or in the presence (B, n=5) of adenosine deaminase (ADA, 1U/ml) to remove 
external endogenous adenosine. The ordinates represent the inhibition caused by BDNF (30 ng/ml), 
where 0% corresponds to absence of effect and 100% to a complete inhibition of GAT-1 mediated 
GABA transport. In each experiment, the effects of BDNF under the drug conditions indicated 
within each panel were always tested using the same synaptosomal batch. BDNF was incubated 
with the synaptosomes for 5 min. All other drugs were added 15 min before BDNF and their 
presence is indicated below each column. ADA (1U/ml) was added 30 min before BDNF. The 
results are mean ± S.E.M.;*p<0.05 as compared with the effect of BDNF in the same experiments 
but absence of CGS 21680 (first column).  
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5.1.6. Discussion 
The experiments described in this chapter were designed to evaluate the effect of 
BDNF on GAT-1 transporter in rat presynaptic nerve terminal. The main findings 
that were achived are that BDNF, through TrkB and PLC signalling inhibits 
GAT-1-mediated GABA transport by nerve endings, and that this action of BDNF 
is not dependent on, but can be enhanced by, cross talk with adenosine A2A 
receptors. The present results contrast with a previous report that BDNF enhances 
GAT-1-mediated GABA transport in serum deprived cultured neurons (Law et al., 
2000). In isolated nerve endings (present work) as in neuronal cultures (Law et 
al., 2000) the effect of BDNF might result from TrkB receptor 
autophosphorylation since it is prevented by a tyrosine kinase inhibitor, K252a. 
The difference may reside in the use of intact cells (Law et al., 2000) versus a 
subcellular fraction specialized in synaptic signalling; the isolated nerve endings 
(present work). Indeed, the intact cells may allow BDNF-induced changes in gene 
expression and protein synthesis, whereas at the nerve endings most of the 
machinery for protein synthesis is lacking. The time course of the BDNF actions 
at the nerve endings and in intact neurons (Law et al., 2000) may also be different, 
since the inhibition of GABA transport at the nerve endings is very fast, being 
already seen after 1 min incubation with BDNF and the used 30 minuts incubation 
time of Law and collaboraters (2000) may be in whole neuron enough to allow 
BDNF-induced changes in protein synthesis (see Caldeira et al., 2007b; Caldeira 
et al., 2007a) for BDNF induced changes in receptor expression). Interestingly, 
the two opposite actions of BDNF upon GAT-1, potentiation of GABA uptake by 
hippocampal neurons (Law et al., 2000) and fast inhibition of GABA uptake now 
demonstrated, may have a coherent physiological goal. Thus, at a nerve ending, 
an inhibition of GABA transport may lead to an increase in the amounts of 
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synaptic GABA, therefore to an increase in GABAergic signalling. On the other 
hand, an increase in GABA transport in other neuronal membrane compartments 
may rescue GABA to replenish the releasable pool. It is also of interest that the 
BDNF-induced inhibition of GABA transport at nerve endings appears to be 
similar when transport is either in the inward direction (present work) or is 
reversed, releasing GABA (Canas et al., 2004). This suggests a common 
mechanism used by BDNF to inhibit GAT-1 at nerve endings, independently of 
the concentration gradient of GABA across the cell membrane. 
The molecular mechanisms that underlie the different ways BDNF uses to 
differentially modulate GAT-1 at nerve endings or entire neurons require further 
studies, but the evidence so far available points towards the involvement of 
different signalling cascades (Osawa et al., 1994; Law et al., 2000). Indeed, TrkB 
receptor signalling includes the activation of the Akt pathway, the activation of 
MAP kinases and the activation of PLC- (see e.g. Chao, 2003). TrkB receptor 
activation by BDNF in hippocampal nerve endings enhances PLC- activity, 
leaving the ERK and Akt phosphorylation pathways unaffected (Pereira et al., 
2006). We observed that the inhibitor of PLC, U73122, prevented the effect of 
BDNF upon GABA transport in isolated nerve endings, but the effect of BDNF 
on GABA transport in the cultured neurons was not affected by PKC inhibition 
(Law et al., 2000). Activation of PLC leads to diacylglycerol formation and 
subsequent PKC activation, which is known to decrease GABA transport (Osawa 
et al., 1994) due to phosphorylation of GAT-1 serine residues (Quick et al., 2004). 
It is therefore not surprising that BDNF, through PLC-mediated signalling, 
decreases GAT-1-mediated GABA transport. However, through promotion of 
phosphorylation of tyrosine residues, BDNF may enhance GABA transport (Law 
et al., 2000). To reconcile these two observations Quick and collaboraters (Quick 
et al., 2004) proposed that the relative abundance of the two mutually exclusive 
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phosphorylation states of GAT-1, one phosphorylated in serine residues and 
another phosphorylated in tyrosine residues, determines the relative subcellular 
distribution of the transporter. However, it is hard to anticipate how the action of 
BDNF, which induces phosphorylation of tyrosine and serine residues, will 
ultimately influence GAT-1. The present data showing that BDNF decreases 
GAT-1-mediated GABA transport at the nerve endings in a PLC-dependent way, 
together with the previous report that BDNF increases GAT-1-mediated transport 
in cultured neurons in a PLC independent way (Law et al., 2000) suggest that the 
subcellular distribution of the transducing systems operated by TrkB receptors 
may decide the fate of BDNF action upon GABA transport.  
The effect of BDNF on synaptosomal GABA uptake was not appreciably affected 
by A2A receptor blockade or removal of endogenous adenosine with adenosine 
deaminase, suggesting that adenosine A2A receptor co-activation is not an 
essential step for this action of BDNF. This contrasts with what has been 
observed by us in what concerns the facilitatory action of BDNF on excitatory 
synaptic transmission (Pousinha et al., 2006; Diógenes et al., 2007) where A2A 
receptor blockade fully prevents the action of BDNF. However, A2A receptors, in 
spite of not being essential, may influence the action of BDNF upon GAT-1 at 
nerve endings since activation of adenosine A2A receptors when they were not 
already occupied by the endogenous ligand, enhanced the BDNF-induced 
inhibition of GABA transport, an enhancement that was antagonized by the A2A 
receptor antagonist. On the light of these results, one could expect that when A2A 
receptors were occupied by the endogenous ligand, i.e., in the absence of 
adenosine deaminase, the A2A antagonist per se would induce at least a slight 
attenuation of the effect of BDNF. The lack of appreciable effect of A2A receptor 
blockade under these conditions may suggest partial A2A receptor desensitization 
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by endogenous adenosine that adds to a low efficacy of A2A receptors to modulate 
the influence of BDNF upon GABA transport.  
BDNF has been shown to quickly modulate GABAergic transmission in the 
hippocampus through pre- and postsynaptic mechanisms. Postsynaptically, BDNF 
decreases GABAergic transmission to pyramidal neurones (Tanaka et al., 1997), 
inducing a rapid downregulation of GABAA receptor surface expression (Brunig 
et al., 2001). Presynaptically, a decrease in GABAergic input to glutamatergic 
neurons has been reported (Frerking et al., 1998). A detailed analysis of the action 
of BDNF at different types of GABAergic synapses revealed that they are synapse 
specific (Wardle and Poo, 2003) but the trend is towards an inhibition of 
GABAergic transmission. The present results showing that BDNF inhibits GABA 
uptake by nerve endings add a new role of BDNF at synapses, which may lead to 
an increase in the lifespan of GABA at GABAergic synapses, counteracting the 
inhibition of GABAergic transmission caused by the neurotrophin. Interestingly, 
in immature neurons BDNF enhances, rather than inhibits, GABA release, and 
this is part of a positive feedback loop between GABA and BDNF expression 
(Obrietan et al., 2002). Since GAT-1-mediated transport in nerve terminals 
appears to contribute to the maturation of point-to-point GABAergic synapses 
(see Conti et al., 1999; Conti et al., 2004), a fine control of GABAergic 
transmission that simultaneously involves BDNF and GAT-1 may be particularly 
relevant in the shaping GABAergic synapses under maturation. Further studies 
are, therefore, required to evaluate how BDNF influences GAT-1 during 
development. 
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5.2. Effects mediated by BDNF on rat astrocyte cultures  
5.2.1. Rationale 
In the previously chapter was shown that BDNF inhibits GABA transport 
mediated by GAT-1 in presynaptic nerve terminal, which therefore shape 
GABAergic transmission. However GABA transporters are also expressed in 
astrocytes, and BDNF at this level can also shape GABAergic transmission. 
Indeed, as mention in detailed at the Introduction, astrocytes, the major class of 
glial cells in the mammalian brain, play a relevant role in synaptic transmission 
and contribute to information processing, since they can control the ionic 
environment of the neuropil and control the supply of several neurotransmitters to 
synapses (Haydon and Carmignoto, 2006; Halassa et al., 2007a; Halassa and 
Haydon, 2010), as well as modulate cell-to-cell communication (Perea et al., 
2009). Astrocytes predominantly express GAT-3 but GAT-1 is also found in this 
type of cells. Although astrocytes play an important role in the regulation of 
extracellular GABA levels (Kirmse et al., 2009), surprisingly little is known on 
how GABA transporters are controlled in these cells. On the other hand, the 
observation that BDNF inhibits GAT-1 mediated GABA transport at the isolated 
nerve endings (see chapter 5.1) but facilitates it in whole neurons (Law et al., 
2000), suggests that this neurotrophin operates in a much localized way and 
eventually in a cell specific manner. Thus in this second part of the work it was 
decided to study the effect of BDNF on GABA transporters, namely GAT-1 and 
GAT-3, in astrocytes.  
The mechanisms underlying the action of BDNF were them investigated taking 
into consideration that regulation of the continuous traffic of GATs to and from 
the neuronal plasma membrane can occur through changes in the endocytosis and 
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exocytosis rates, and/or the number of transporters available for recycling (Deken 
et al., 2003). For instance surface expression of GAT-1 in cultured neurons 
(Beckman et al., 1999; Wang and Quick, 2005) and isolated nerve terminals 
(Cristovão-Ferreira et al., 2009) is decreased by protein kinase C (PKC)-
dependent phosphorylation. In contrast, surface expression of GAT-1 in neurons 
is enhanced by brain derived neurotrophic factor (BDNF)-mediated tyrosine 
kinase-dependent phosphorylation (Law et al., 2000; Whitworth and Quick, 
2001).  
Finally, since in nerve terminals the regulation of GAT-1 by BDNF is modulated 
by activation of adenosine A2A receptors (see chapter 5.1 and Vaz et al., 2008), as 
it was observed for other fast BDNF actions (for a review see Sebastião et al., 
2010), it was next evaluated how adenosine could modulate BDNF effects upon 
GABA transporters in astrocytes. 
5.2.2. BDNF increases GAT-1-mediated GABA uptake by increasing Vmax 
constant of the transporter on astrocyte cultures 
GABA transport into the astrocytic culture was first characterized by evaluating 
the maximum velocity (Vmax) and affinity constant (Km) for GAT-1 transport, and 
the relative contribution of GAT-1 and GAT-3 for total GABA transport. The Km 
value obtained for GABA uptake in astrocytes was around 30 µM, a value similar 
to the one already reported by others (Schousboe et al., 2004). When we isolated 
GAT-1 and GAT-3 mediated GABA transport (see methods, Figure 5.2.1A), the 
obtained Km value was 4.7 ± 1.89 µM (n=6, open circles) and 10.1 ± 3.20 µM 
(n=4, filled circles), for GAT-1 and GAT-3 transporters respectively, values also 
of the same magnitude to previously reported in relation to these transporters 
(Wood and Sidhu, 1986; Schousboe et al., 2004).  
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The uptake of GABA in the presence of the selective GAT-1 inhibitor, 
SKF89976a (20 µM), was reduced by 38 ± 5.8 % (n=5) of total uptake; when 
GAT-3 was blocked with SNAP 5114 (20 µM), a selective inhibitor of GAT-3 
transporter, GABA transport was reduced by 53 ± 2.8 % (n=5). These data 
indicates that near 55 % total GABA transport into astrocytes occurs through 
GAT-3, the remaining 40% being through GAT-1 (Figure 5.1.2.B). From now on, 
while refering to GAT-1 mediated GABA transport I am reporting data from 
experiments where GAT-1 had been blocked with a supramaximal concentration 
(20 µM) of SKF 89976a (Borden et al., 1994a), being the transport mediated by 
GAT-1 calculated by the difference between total transport (absence of GAT-1 
blocker) and the transport measured in presence of GAT-1 blocker in the same 
experiment. Conversely, when we refer to GAT-3 mediated GABA transport we 
are referring to experiments where GAT-3 had been blocked with a supramaximal 
concentration (20 µM) of SNAP 5114 (Borden et al., 1994b), the GAT-3 
mediated transport being calculated by the difference between total transport and 
transport in the presence of the GAT-3 blocker in the same experiment. 
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Figure 5.2.1. Characterization of GABA transport in astrocytes. A. Saturation analysis of GAT-
1 (open circles, n=6) and GAT-3 (filled circles, n=4) transporters; data shown in the upper panel are 
the mean values from four experiments performed in quadruplicate (four wells per GABA 
concentration); the averaged Km (Michaelis constant) and Vmax (maximal velocity) values being 
shown in the lower panel. B. Percentage of GABA uptake that occurs through GAT-1 (open bar, 
n=5) and GAT-3 (filled bar, n=5) GABA transporters. The GAT-1 transporter was isolated by using 
GAT-1 transporter inhibitor SKF89976a (20 µM), while GAT-3 transporter was isolated by using 
GAT-3 inhibitor SNAP5114 (20 µM). The results are expressed as mean ± SEM. 
 
As it can be observed in Figure 5.2.2A, BDNF (10-30 ng/ml) caused a 
concentration-dependent increase in GAT-1 mediated GABA transport in 
astrocytes, the effect of 10 ng/ml BDNF being of 30 ± 8.0% (n=7, p<0.05) 
increase. GAT-3 mediated transport remained, however, unaffected.  
            A.                                                                           B.                               
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Changes in the uptake of neurotransmitters induced by transporter-interacting 
compounds can result from alterations in the turnover rate of transporters that 
reflects in the number of functional transporters at the cytoplasmatic membrane, 
or from changes in the transport capacity of individual transporters. Data obtained 
from saturation experiments are often used to distinguish between these two 
possibilities, since changes in the maximum velocity of transport (Vmax) are 
indicative of changes in the number of transporter binding sites, that are 
correlated with translocation of transporter to or from plasma membrane, and 
changes in affinity (Km) are indicative of changes in the function of individual 
transporters. Michaelis-Menton fitting of saturation curves for GAT-1 mediated 
GABA transport into astrocytes reveal a significant (p<0.05, n=6) increase in Vmax 
in the presence of BDNF (10 ng/ml) compared to untreated cells from the same 
culture (Figure 5.2.2B). Km values were not significantly (p>0.05) affected by 
BDNF (Figure 5.2.2B) 
From the time course of the effect of BDNF (10 ng/ml) upon GAT-1 mediated 
GABA transport (Figure 5.2.3) it is clear that the effect of BDNF occurs within 
minutes after its application, with the half maximal effect being observed after 
about 2 min and the maximal effect after 10 minutes of its application. Increasing 
the incubation time up to 30 min did not alter the effect of BDNF, as compared 
with 10 min incubation. Wash-out experiments performed after a 30 min 
incubation period showed that the effect of BDNF was reversible (Figure 5.2.3), 
with GABA uptake values being back to control levels 30 min after removing the 
neurotrophin from the incubation medium. In the remaining experiments, a 10 
min incubation period with BDNF was used. 
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Figure 5.2.2. BDNF enhances GAT-1 GABA transport in astrocyte primary cultures. A. 
Saturation analysis of GAT-1 mediated GABA transport in presence of BDNF; cells were incubated 
in the absence (open circles) or presence of 10 ng/ml BDNF (filled circles) before addition of 
[3H]GABA at the concentrations indicated in the abscissa; data shown in the upper panel were the 
mean values from six experiments performed in quadruplicate (four wells per GABA 
concentration); the averaged Km (Michaelis constant) and Vmax (maximal velocity) values being 
shown in the lower panel; *P < 0.05 (Student’s t test, as compared with control). B. Influence of 
BDNF upon GAT-1 (open bars) or GAT-3 (filled bars)-mediated GABA transport; *P < 0.05 (one-
way ANOVA followed by the Bonferroni’s post-test, as compared with control). The results are 
expressed as mean ± SEM from 6 (A) or 7 (B) independent experiments. BDNF was incubated 
with astrocytes for 10 min.  
            A.                                                             
A.                      
B.                 
Modulation of GAT-1 transporters by BDNF and A2A receptors 
 
 88
 
 
 
 
 
 
 
 
 
Figure 5.2.3. Time-course of BDNF (10 ng/ml) effect. The effect of BDNF is reversible upon drug 
washout. The ordinates represent the [3H]GABA uptake relative to uptake in the absence of BDNF 
(100% ) in the same experiments. The results are expressed as mean ± SEM from 5 independent 
experiments. BDNF was incubated with astrocytes as indicated below each time point.  
 
5.2.3. Modulation of GAT-1 by BDNF occurs through the truncated TrkB 
receptor isoform.  
BDNF operates through high-affinity receptor tyrosine kinase B, TrkB, which 
exists in at least two isoforms, a full length isoform (TrkB-fl) and a truncated 
isoform (TrkB-t) (see e.g. Chao, 2003). Only the TrkB-fl possesses the catalytic 
kinase domain and tyrosine kinase inhibitors, such as K252a (Tapley et al., 1992) 
can thus be used to evaluate if a given effect of BDNF occurs through TrkB-fl or 
through another receptor isoform. We first evaluated whether tyrosine 
phosphorylation of GAT molecules could play a role in the functional regulation 
of GABA transport in astrocytes. For this purpose, astrocytic cultures were treated 
with K252a and changes in Km and Vmax values were calculated from Michaelis-
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Menton fitting of saturation curves. K252a induced a significant (p<0.05, n=5) 
decrease in Vmax of GAT-1 (Figure 5.2.4A) and GAT-3 (Figure 5.2.4B) mediated 
transport, without significant (p>0.05) changes in Km values. It is worthwhile to 
note that data obtained with K252a somehow contrasts with that obtained with 
BDNF since while the neurotrophin affects GAT-1 but not GAT-3 mediated 
transport, the inhibitior of tyrosine phosphorylation affects both transporters.  
To evaluate if the effect of BDNF requires a tyrosine phosphorylation signalling 
cascade, it was decided to test first if K252a could prevent the effect of BDNF. 
Given the marked inhibitory effect of K252a per se, the strategy was to compare, 
within the same astrocytic culture, GABA transport under the following 4 
different conditions: no drug added, only BDNF added, only K252a added and 
BDNF added in the presence of K252a, therefore allowing the comparison of the 
effect of BDNF under similar conditions, in the absence and in the presence of 
K252a. From data shown in Figure 5.2.4C, it is evident that in spite of the 
presence of K252, BDNF was able to enhance GABA transport. Indeed, upon 
calculation of the effect of BDNF as % increase, i.e. taking as control the 
transport of GABA in the same drug conditions but absence of BDNF, it became 
clear that BDNF increased GABA transport by 31 ± 4.4 % (n=6, p<0.05) in the 
absence of K252a (value calculated by considering the control condition as 100%) 
and by 32 ± 4.9 % (n=6, p<0.05) in the presence of K252a (value calculated by 
considering the K252a treated astrocytes condition as 100%) with no statistically 
significant differences (n=6, p>0.05) between both BDNF effects. These results 
indicate that tyrosine kinase activity is not required for the effect of BDNF, 
therefore are highly suggestive of a non TrkB-fl mediated effect.  
In accordance with the results obtained with K252a, data from Western Blot 
analysis showed that cultured astrocytes express TrkB-t receptors but not TrkB-fl 
receptors. Indeed, a band corresponding to the molecular weight of TrkB-fl 
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isoform (145 kDa) was never detected in the Western Blots of homogenates of 
astrocytic cultures, while the TrkB antibody clearly recognized a 95 KDa protein 
in the samples, a molecular weight compatible with the one of the TrkB-t isoform 
(Figure 5.2.4D). As a control for the antibody used, homogenates from cultured 
hippocampal neurons, non-treated or treated with 10 ng/ml BDNF, were also 
assayed and, as illustrated in Figure 5.2.4D, a 145 KDa protein corresponding to 
the molecular weight of the TrkB-fl was clearly detected in the neurons. Since 
activation of TrkB-fl by BDNF leads to receptor autophosphorylation, we 
assessed the levels of pTrkB in astrocyte and neurons treated with BDNF (10 
ng/ml) by using an antibody against pTrkB. It became clear that pTrkB staining 
could be detected in neurons but not astrocytes (Figure 5.2.4D). Altogether, this 
data strongly suggest that astrocytes express the truncated form but virtually not 
the full length form of the TrkB receptor. Interestingly, exposure of astrocytes to 
different concentrations of BDNF (10 - 30 ng/ml) for 10 minutes, leads to a 
concentration-dependent increase (p<0.05, n=4) in the expression of TrkB-t 
receptor on the surface membrane, as assessed by Western Blot analysis of the 
biotinylated astrocyte membrane fractions (Figure 5.2.4E).  
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Figure. 5.2.4. BDNF modulates GAT-1 through activation of TrkB-t receptor. Saturation 
analysis of GAT-1 (A) and GAT-3 (B) transport; cells were incubated in the absence (open circles) 
or presence of the non-selective tyrosine kinase inhibitor, 200nM K252a (filled circles) before 
addition of [3H]GABA at the concentrations indicated in the abscissa; data shown in the upper panel 
are the mean values from five experiments performed in quadruplicate (four wells per GABA 
concentration); the averaged Km (Michaelis constant) and Vmax (maximal velocity) values being 
shown in the lower panel; *p<0.05 (Student’s t test, as compared with control). C. Effect of BDNF 
upon [3H]GABA uptake in the presence or absence of K252a; *p<0.05 (one-way ANOVA followed 
by the Bonferroni’s post-test, as compared with control conditions (1st bar in the left) except where 
otherwise indicated by the connecting lines above the bars. D. Analysis of TrkB and pTrk staining 
in total lysates of astrocytes or neurons treated with/without 10 ng/ml BDNF, as indicated. E. 
Western Blot analysis of TrkB-t immunoreactivity in cell lysates and biotinylated (surface) fractions 
of astrocytes. In the left panel is shown a representative immunoblot and in the right panel depicts 
the quantitative densitometric analysis of the immunoreactivity in the biotinylated fraction; blots 
were probed with anti-TrkB (1:1000); β-actin immunolabelling (1:10000, 43 kDa band) was used as 
a loading control. In C 100% in the ordinates correspond to the amount of [3H]GABA taken up by 
astrocytes in the same experiments in the absence of any drug; in E 100% in the ordinate 
corresponds to TrkB-t staining in the absence of BDNF, after normalization for β-actin 
immunoreactivity. The results are expressed as mean ± SEM from 5 (A and B), 6 (C) or 4 (E) 
independent experiments. 
 
Experiments were then designed to assess signalling pathways involved in the 
modulatory action of BDNF upon GAT-1. The effect of BDNF in absence and in 
presence of inhibitors of known TrkB-fl signalling cascades were compared in the 
same astrocytic cultures. As shown in Figure 5.2.5A, the PI3-K inhibitor 
LY294002 (10 µM, Ding et al., 1995) had no significant inhibitory effect on 
GAT-1 mediated GABA uptake (p>0.05, n=4); also, it did not prevent the 
facilitatory action of BDNF, which remained virtually unchanged in the presence 
of this inhibitor. On the other hand, inhibition of the ERK/MAP kinase signalling 
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pathway with the selective MEK1 and 2  inhibitor U0126  (10 µM, Favata et al., 
1998) had no effect upon GABA transport in rat astrocytes when tested alone, but 
fully prevented the facilitatory effect of BDNF on GAT-1 mediated GABA 
transport. Indeed, GAT-1 mediated GABA uptake in astrocytes in the presence of 
U0126 (10 µM) was not significantly (n=4, p>0.05) altered by BDNF (10 ng/ml) 
(Figure 5.2.5A). Likewise, the PLC- inhibitor U73122  (3 µM, Smith et al., 
1990) also prevented the effect of BDNF while being by itself devoid of effect 
(p>0.05, n=4, Figure 5.2.5A) upon GABA transport. These results suggest that the 
BDNF-induced increase in GAT-1 mediated GABA uptake involves the activity 
of at least two transduction pathways, namely the PLC- and the Erk/MAP kinase 
pathways. Since TrkB receptor activation coupled to PLC- phosphorylation leads 
to a subsequent activation of PKC-δ (Patapoutian and Reichardt, 2001), and in 
order to assess if PKC-δ is involved in the BDNF-induced GAT-1 modulation, I 
tested the influence of the PKC-δ inhibitor, GF109203x (1 µM, Toullec et al., 
1991). This inhibitor per se did not affect GAT-1 mediated GABA transport, but 
abolished the effect of BDNF, also implicating PKC-δ in the signalling cascade. 
BDNF (10 ng/ml) induced a significant increase of the phosphorylation state of 
PLC and MAP kinase (p<0.05, n=3), but no alteration for the phosphorylation 
state of Akt (Figure 5.2.5B), which fits to the results obtained in uptake 
experiments with PI3-K, ERK/MAP kinase or PLC-δ blockers. Summarizing, the 
results so far suggest that BDNF-induced modulation of GAT-1 is not mediated 
by TrkB-fl, since it does not involve phosphorylation at tyrosine residues, and that 
it is most likely mediated through a TrkB-t isoform coupled to a non classic PLC 
and Erk/MAP kinase mechanism, involving PKC-δ. 
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Figure 5.2.5. Transduction pathways involved in GAT-1 modulation by BDNF. A. Effect of 
BDNF upon [3H]GABA uptake in the presence of inhibitors of the different signal transducing 
pathways of TrkB receptor, namely, the PLC-δ inhibitor, U73122, the PI3-K inhibitor, LY294002, 
the MEK Kinase inhibitor, U0126, and the PKC-δ inhibitor, GF109203x (see text for references) as 
indicated below the bars. B. Western blot analysis of PLC/pPLC, Akt/pAkt and MAPK/pMAPK 
staining in total lysates of cells treated with 10 ng/ml BDNF, as indicated. In the upper panels are 
shown representative immunoblots and the lower panels depicts the quantitative densitometric 
analysis of the immunoreactivity of phosphorylated proteins; blots were probed with anti-PLC 
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(1:750), pPLC (1:250), Akt (1:1500), pAkt (1:500), MAPK (1:6000) and pMAPK (1:500). In A 
100% in the ordinates correspond to the amount of [3H]GABA taken up by astrocytes in the same 
experiments in the absence of any drug; in B 100% in the ordinate corresponds to PLC/pPLC, 
Akt/pAkt or MAPK/pMAPK staining in the absence of BDNF. All enzyme inhibitors were added 20 
minutes before BDNF, which was added to cells 10 minutes before [3H]GABA. The results are 
expressed as mean ± SEM from 4 (A) or 3 (B) independent experiments. *p<0.05 (one-way 
ANOVA followed by the Bonferroni’s post-test, as compared with no drug (1st bar in the left) or, 
whenever indicated, with the closest bar in the left (absence of BDNF under same drug conditions). 
 
5.2.4. Incorporation of an HA epitope into EL2 of GAT-1 does not affect 
GAT-1 affinity for GABA neither sensitivity to BDNF  
To test the hypothesis that BDNF increases GABA uptake through GAT-1 by 
increasing the density of transporters at cell surface, the stretagy was to generate a 
functional rat GAT-1 transporter that has an antibody accessible extracellular 
epitope enabling the measurement of changes in rGAT-1 surface expression by 
ELISA. For the closely related dopamine transporter, an HA-epitope has 
previously been inserted into the extracellular loop 2 (EL2) without altering the 
function of the transporter (Sorkina et al., 2006). Accordingly, an HA tag of nine 
amino acid residues (YPYDVPDYA) was introduced in the EL2 loop of rGAT-1 
in different locations in order to obtain a construct kinectically similar to wild 
type rGAT-1 transporter (Figure 5.2.6A). Thus four different constructs 
containing the HA tag were designed: HA1-rGAT-1 where the tag was inserted 
between the residues 693 and 694, HA2-rGAT-1 where the tag was inserted 
between the residues 698 and 699, HA3-rGAT-1 where the tag was inserted 
between the residues 706 and 706 and HA3-rGAT-1 where the tag was also 
inserted following the residue 706 but where the following 11 residues were 
removed (Figure 5.2.6A).  
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HA epitope: YPYDVPDYASL (previously described for the homoge  
DAT by Sorkina et al., 2006) 
 
Sequence in rGAT surrounding the glycosylation sites: 
-Asn-Tyr-Ser-Leu-Val-Asn-Thr-Thr-Asn-Met-Thr-Ser-Ala-Val- 
Blue = glycosylation site (Asn-X-Ser/Thr) 
 
HA1: Asn-Tyr-Ser-HA-Val-Asn-Thr-Thr-Asn-Met-Thr-Ser-Ala-Val 
HA2: Asn-Tyr-Ser-Leu-Val-Asn-Thr-Thr-HA-Asn-Met-Thr-Ser-Ala-Val 
HA3: Asn-Tyr-Ser-Leu-Val-Asn-Thr-Thr-Asn-Met-Thr-HA-Val 
HA4: Asn-Tyr-Ser-Leu-Val-Asn-Thr-Thr-Asn-Met-Thr-HA - (the 
following 11 amino acids deleted) 
 
 
 
 
 
 
 
 
 
 
 
 
                A.                                                             
                B.                                                               
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Figure 5.2.6. The schematic structure and characterization of HAs-GAT-1. A. The HA tag was 
placed in the second extracellular loop of rGAT-1. Predicted N-glycosylation sites in the EL2 are 
indicated as well as the location of HA tag in the different inserts B. Saturation kinetics of GAT-1-
mediated GABA uptake in HEK293 cells stably expressing HAs-GAT-1 as indicated. The Km 
(Michaelis constant) and Vmax (maximal velocity) values calculated by non-linear regression analysis 
(GrapPad software) are shown bellow the graph. 
 
Kinetic measurements of [3H]GABA uptake into HEK293 cells expressing the 
different HA-rGAT-1 constructs (Figure 5.2.6B) yielded different Km values, 
being the HA2-GAT-1 (4.2 ± 1.35 µM, n=3) the construct that did not differ from 
the Km value obtained in HEK293 cells expressing wild type rGAT-1 (7.70 ± 2.90 
µM, n=3) (Figures 5.2.7A and 5.2.7C). Notably, the Km values obtained in 
HEK293 cells expressing rGAT-1 or HA2-rGAT-1 were similar to the Km value 
for rGAT-1 endogenously expressed in astrocyte primary cultures (Figure 5.2.7A, 
5.2.7C and 4.2.1A). The Vmax values for all HAs-rGAT-1 expressed in HEK293 
(Figure 5.2.6B) were significantly different from the value obtained in a parallel 
experiments on cells expressing wild type rGAT-1 (Figure 5.2.7C). Nevertheless, 
since the HA2-GAT-1 was the construct with more similar Km value to wild type 
rGAT-1, it possible to deduce with these uptake experiments, that introduction of 
the HA-epitope in EL2, between the residues 698 and 699, yielded a functional 
transporter that was expressed at the cell surface (although to a lower extent than 
the wild type transporter) and had an unaltered apparent affinity for GABA. Thus 
the HA2-GAT-1 was the selected contruct to proceed with the following 
experiments and from now on HA2-GAT-1 will be referring as HA-GAT-1. 
Next step was to evluate the expression of HA-rGAT-1 in rat astrocytes. 
Following transduction of astrocytes with lentivirus encoding HA-rGAT1, GABA 
uptake was increased more than twofold compared to non-transduced astrocytes 
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(Figure 5.2.7B). Treatment of astrocytes that were transduced with HA-rGAT-1 
with BDNF (10 and 30 ng/ml) revealed an increase of GABA uptake that was 
similar to BDNF effect upon astrocytes that were not expressing HA-rGAT-1 
(Figure 5.2.7D). The effect of BDNF on GABA uptake in HA-rGAT-1 transduced 
astrocytes was maximal already with a 10 ng/ml BDNF concentration; indeed for 
the 10 ng/ml BDNF concentration it was observed an increase of 45.0 ± 12.14 % 
of GABA uptake through GAT-1 transporter. It is important to mention that 
results of BDNF action on GABA transport presented in Figure 5.2.7D, with both 
non-transduced and transduced astrocytes, were obtained simultaneously and with 
the same batch of cells, indicating that HA-rGAT-1 and endogenous rGAT-1 have 
similar sensitivity to BDNF. 
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Figure 5.2.7. Characterization of HA-GAT-1 mediated GABA transport. A. and C. Saturation 
kinetics of GAT-1-mediated GABA uptake in HEK293 cells stably expressing HA2-GAT-1 (B, 
n=3) or rGAT-1 (C, n=3) The Km (Michaelis constant) and Vmax (maximal velocity) values 
calculated by non-linear regression analysis (GrapPad software) are shown as an inset in the 
corresponding graph. B. [3H]GABA uptake trough GAT-1 in HA-GAT-1 transduced (n=2) and non-
transduced (n=2) astrocytes. The ordinates represent the [3H]GABA uptake as pmol of GABA 
transported per min, mediated by GAT-1 transporter; values are mean ± S.E.M values (n=2); note 
that the transduction of astrocytes with HA-rGAT-1 increased GABA uptake. D. BDNF effects on 
GABA uptake in HA-rGAT-1 transduced and non-transduced astrocytes from the same cell batch 
(n=5). Note that BDNF increased GABA uptake in both non-transduced and HA-rGAT-1 
transduced astrocytes. The ordinates represent the [3H]GABA uptake as percentage of the control 
value (no BDNF added) in the same experiment and in the same cell batch in similar conditions. 
GABA uptake assays were performed for 1 min at 37°C using 8.62 nM [3H]GABA and increasing 
    A.                                                            B.                                                             
C.                                                                    D.                               
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amounts of unlabeled GABA (A and C; final concentrations, 1 to 50 µM), or a mixture of 8.62 nM 
[3H]GABA with unlabeled GABA to a final concentration of 30 µM GABA (B and D) . Non-GAT-
1-mediated uptake was determined in the presence of 20 µM SKF89976a. In all panels the results 
are mean ± S.E.M. *p<0.05 (one-way ANOVA followed by the Bonferroni’s post-test) as compared 
with control (no drug added, first column in the left) in the same group of cells. 
 
5.2.5. BDNF enhances translocation of rGAT-1 to plasma membrane of 
astrocytes 
The influence of BDNF upon GAT-1 trafficking in rat astrocytes was first 
assessed by cell surface ELISA using an antibody against the HA tag. HA-rGAT-
1 transduced astrocytes were incubated with BDNF (10-100 ng/ml) for 10 min 
before the assay, inducing a significant increase (20.1 ± 12.90 %, 32.2 ± 8.97 %, 
and 39.9 ± 6.68 % for 10, 30 and 100 ng/ml of BNDF, respectively, n=4, p<0.05) 
in immunodetected HA tagged surface transporter as compared to astrocytes that 
were not incubated with the neurotrophin (Figure 5.2.8A).  
To rule out the possibility that the effect of BDNF upon trafficking was related to 
the HA tag, biotinylation experiments using astrocytes not transfected with the 
HA tagged GAT-1 were performed. Since GAT-1 levels in biotinylated astrocytic 
membranes are below the detection limit by Western Blot (data not shown), 
rGAT-1 was overexpressed in the astrocytes by transduction with lentivirus 
encoding wild type rGAT-1. Cells were then incubated in the absence or presence 
of BDNF before biotinylation of surface proteins. As shown in the representative 
immunoblot (Figure 5.2.8B, upper panel) and in summary plot (Figure 5.2.8B, 
lower panel), incubation of cells with BDNF for 10 min leads to an increase (17.7 
± 5.38 and 20.9 ± 4,76 %, for 10 or 30 ng/ml BDNF, respectively, n=5, p<0.05,) 
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in GAT-1 immunoreactivity in the biotinylated fraction, without appreciable 
change in total GAT-1 immunoreactivity.  
Altogether, the data above clearly shows that BDNF enhances the expression of 
GAT-1 transporters at the plasma membrane. To assess whether BDNF affects the 
rate of internalization of GAT-1 or its recycling back to the plasma membrane, we 
tested the influence of dynasore, a dynamin inhibitor therefore blocking 
dynamin/clathrin dependent endocytosis (Macia et al., 2006) as well as of the 
cation ionophore monensin, which blocks protein recycling back to the membrane 
without influencing protein internalization (Mollenhauer et al., 1990). Monensin, 
used in conditions (25µM, 1h) previously shown shown to inhibit recycling of 
dopamine transporters in neuronal cell lines (Eriksen et al., 2010) slightly 
decreased GABA uptake by around 10% (n=5, Figure 5.2.8C), suggestive of 
constitutive recycling of GAT-1 in astrocytes. Similarly, biotinylation assays 
showed that monensin slightly decreases GAT-1 expression at surface membranes 
(n=3, Figure 5.2.8D). In the presence of monensin, however, BDNF still increased 
GAT-1 mediated GABA uptake by 26 ± 10.2 % (n=5, p<0.05, Figure 5.2.8C) as 
well as GAT-1 expression at surface membranes (n=3, P<0.05, Figure 5.2.8D). 
This suggests that BDNF does not operate by enhancing GAT-1 recycling back to 
the plasma membrane. The dynamin inhibitor, dynasore (70 µM) increased GAT-
1 mediated GABA uptake by 24 ± 6.1 % (n=5, p<0.05, Figure 5.2.8C) as well as 
increased GAT-1 expression at surface membranes (Figure 5.2.8D) indicating that 
in astrocytes, as it occurs in neurons (5), GAT-1 internalization involves the 
dynamin/clathin-dependent mechanism, rather than the Ca2+ regulated dynamin-
independent endocytotic pathway, which is also present in cortical astrocytes 
(Jiang and Chen, 2009). Dynasore (70 µM) fully abrogates the facilitatory effect 
of BDNF upon GAT-1 mediated GABA transport (n=5, Figure 5.2.8C) as well as 
upon GAT-1 expression at surface membranes (n=3, Figure 5.2.8D) therefore 
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indicating that BDNF inhibits constitutive internalization of GAT-1 rather than 
enhances the insertion/recycling pathway. 
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Figure 5.2.8. BDNF enhances surface expression of GAT-1 in astrocytes. A, HA-rGAT-1 
transduced astrocytes were incubated for 10 min with (+) or without (-) BDNF (10-30 ng/ml) as 
indicated below each bar and then assayed by ELISA. 100% in the ordinates represent normalized 
HA-GAT-1 expression in plasma membrane of astrocytes in control situation (absence of BDNF). 
B. rGAT-1 transduced astrocytes were incubated as in A, but changes in surface GAT-1 
immunoreactivity were assessed by surface biotinylation. In the upper panel, is shown a 
representative immunoblot from total lysate and biotinylated (surface membrane) astrocyte 
fractions; blots were probed with anti-GAT-1 (1:500, 67 kDa band); β-actin (1:10000, 43 kDa band) 
immunoreactivity was used as loading control; in the lower panel is shown the average 
densitometric analysis, where 100% in the ordinates represent normalized rGAT-1 expression in the 
biotinylated fraction in the absence of BDNF. C and D: Influence of monensin, an inhibitor of 
insertion/recycling pathway, and dynasore, a dynamin inhibitor (see text for references) upon the 
effect of BDNF on GABA uptake (C) or surface expression of rGAT-1 (D); in the upper panel in 
(D) is shown a representative immunoblot from total lysate and biotinylated (surface membrane) 
astrocyte fractions, and in lower panel is shown the average densitometric analysis, where 100% in 
the ordinates represent normalized rGAT-1 expression in the biotinylated fraction in the absence of 
BDNF. The results are expressed as mean ± SEM from 4 (A), 5 (B and C) or 3 (D) individual 
experiments. *p<0.05 (one-way ANOVA followed by the Bonferroni’s post-test), as compared with 
control conditions (1st column in the left) except where otherwise indicated by the connecting lines 
above the bars; NS: non-statistically significant (p>0.05). 
 
5.2.6. Tonic levels of extracellular adenosine are enough to trigger the 
effect of BDNF. 
It has been repeatedly observed that actions of BDNF at synapses require co-
activation of adenosine A2A receptors, a mechanism that involves activation of 
PKA and TrkB translocation to lipid rafts (Diógenes et al., 2007; Assaife-Lopes et 
al., 2010). An exception is BDNF-induced inhibition of GABA transport into 
nerve terminals, since the effect of BDNF on GAT-1 in nerve terminals is not 
prevented by removal of extracellular adenosine or by blockade of adenosine A2A 
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receptors (Vaz et al., 2008). In order to evaluate if adenosine A2A receptors could 
influence the facilitatory action of BDNF on GAT-1 mediated GABA transport 
into astrocytes we tested whether A2A receptor blockade with a selective 
antagonist, SCH 58261 (50 nM, Zocchi et al., 1996b), or A2A receptor activation 
with a selective agonist, CGS 21680 (30 nM, Jarvis et al., 1989) affected the 
action of BDNF. Per se, these drugs did not significantly (N=4, p>0.05) affect 
GABA transport, though there was a tendency for a facilitation by the A2A 
receptor agonist and an inhibition by the A2A receptor antagonist (Figure 5.2.9A). 
Similarly, adenosine deaminase (ADA, 1U/ml), an enzyme that catabolises 
adenosine into inosine, therefore removing extracellular adenosine caused a slight 
but non-significant decrease in GAT-1 mediated GABA transport (n=4, p>0.05). 
To evaluate the effect of BDNF in the presence or absence of the A2A receptor 
ligands, experiments were designed so that GABA transport in the presence of 
each A2A receptor ligand was taken as control for the effect of BDNF, which was 
tested in the same astrocytic culture in the absence or in the presence of the 
ligand. A summary of the results is shown in Figure 5.2.9C. The facilitatory effect 
of BDNF was fully lost upon incubation of astrocytes with the A2A receptor 
antagonist, SCH 58261 (50 nM, n=8). The same occurred when extracellular 
endogenous adenosine was removed by incubating the cells with ADA (1 U/ml, 
n=4, Figure 5.2.9C). Activation of A2A receptors with CGS 21680 (30 nM) caused 
a slight but non-significant (n=4, p>0.05, Figure 5.2.9C) enhancement of the 
facilitatory action of BDNF, suggesting that tonic activation of A2A receptors by 
endogenous adenosine is enough to fully trigger the facilitatory effect of BDNF 
on GAT-1 mediated GABA transport into astrocytes. A similar conclusion can be 
drawn from evaluating the facilitatory action of BDNF upon surface expression of 
GAT-1 (Figure 5.2.9D) or BDNF-induced enhancement of TrkB-t surface 
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expression (Figure 5.2.9E), since in no case a further activation of A2A receptors 
with GCS 21680 induce a further effect of BDNF. 
Activation or inhibition of the canonical signal transducing pathway of adenosine 
A2A receptors should influence the effect of BDNF in a way similar to what is 
observed when A2A receptor activity is manipulated by receptor ligands. 
Accordingly, the adenylate cyclase activator, forskolin (5 µM, Awad et al., 1983), 
did not cause a further enhancement of the effect of BDNF (n=6, Figure 5.2.9B), 
whereas the protein kinase A inhibitor, H-89 (10 µM, Murray, 2008), fully 
prevented the effect of BDNF on GAT-1 mediated GABA transport (n=6, Figure 
5.2.9B). Upon activation of adenylate cyclase with forskolin, the A2A receptor 
antagonist was no longer able to block the effect of BDNF (n=4, Figure 5.2.9B) 
strongly indicating that blockade of the action of BDNF by A2A receptor 
antagonism is upstream of adenylate cyclase, therefore reinforcing the conclusion 
that A2A receptors operate through this transducing pathway to allow BDNF 
actions upon GABA transport into astrocytes.  
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Figure 5.2.9. Modulation of the effect of BDNF by adenosine A2A receptors. A. Influence of A2A 
receptor activation with a selective agonist, CGS 21680, or blockade with a selective antagonist, 
SCH 58261, or removal of extracellular adenosine with adenosine deaminase (ADA) on [3H]GABA 
uptake mediated by GAT-1. B. Influence of drugs that affect cAMP signaling upon the effect of 
BDNF on [3H]GABA uptake; forskolin was used as an activator of adenylate cyclase and H-89 as an 
inhibitor of PKA (see text for references). C. Influence of CGS 21680, SCH 58261 and ADA on the 
effect of BDNF upon [3H]GABA uptake. D and E. A2A receptor agonist, CGS 21680, affects on the 
BDNF-induced increase in surface expression of GAT-1 (D) or TrkB-t (E). In the upper panels are 
shown, representative immunoblots for GAT-1 (D) and TrkB-t (E) immunoreactivity in cell lysate 
and biotinylated fractions of astrocytes; blots were probed with anti-GAT-1 or anti-TrkB antibodies; 
β-actin immunoreactivity was used as loading control; in the lower panel is shown the average 
densitometric analysis, where 100% in the ordinates represent rGAT-1 expression or TrkB-t levels 
(both normalized for β-actin in the same lane) in the biotinylated fraction in the absence of BDNF. 
For A, B and C, 100% in the ordinates correspond to the amount of GABA taken up in the absence 
of any drug. In all panels data is expressed as mean ± S.E.M from 4-8 (A, B and C) or 6 (D and E) 
individual experiments. Drug presence (+) or absence (-) is indicated below each bar. *P<0.05 (one-
way ANOVA followed by the Bonferroni’s post-test), as compared with control conditions (no 
BDNF added) except where otherwise indicated by the connecting lines above the bars; NS: non-
statistically significant (p>0.05). 
 
Finally, it was evaluated whether the BDNF-induced enhancement of the 
phosphorylation state of PLC and MAP kinase (Figure 5.2.5B) was also under 
control of adenosine A2A receptors. As shown in Figure 5.2.10, BDNF-induced 
phosphorylation of PLC and MAP kinase was also fully blocked by the A2A 
receptor antagonist, SCH 58261 (50 nM) but not significantly affected by a 
further activation of A2A receptors with the agonist, CGS 21680 (30 nM), 
therefore mimicking what we observed while measuring GABA transport. Per se, 
neither the A2A receptor agonist (CGS 21680, 30 nM) nor the antagonist (SCH 
58261, 50 nM) significantly affected the phosphorylation state of PLC and MAP 
kinase in astrocytes.  
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Figure 5.2.10. A2A receptor mediated modulation of the signalling pathways activated by 
BDNF. Western blot analysis of PLC/pPLC (A) and MAPK/pMAPK (B) staining in total lysates of 
cells treated with BDNF, CGS 21680 and SCH 58261, as indicated. In the upper panels are shown 
representative immunoblots for PLC/pPLC (A) and MAPK/pMAPK (B) in cell lysate; in lower 
panels are shown the average densitometric analysis, where the ordinates represent quantitative 
densitometric analysis of immunoreactivity of phosphorylated proteins; data is expressed as mean ± 
S.E.M from 6 (A) or 4 (B) individual experiments. *p<0.05 (one-way ANOVA followed by the 
Bonferroni’s post-test), as compared with no drug conditions (1st column in the left) except where 
otherwise indicated by the connecting lines above the bars; NS: non-statistically significant 
(p>0.05). 
 
5.2.7. Discussion 
The main finding of the present work is that BDNF increases GAT-1 mediated 
GABA transport into astrocytes through a mechanism that involves the TrkB-t 
isoform of TrkB receptors and a non classic PLC-γ/PKC-δ and Erk/MAP kinase 
pathway, leading to enhanced expression of GAT-1 at the cell surface due to a 
reduced internalization. 
BDNF facilitates the maximum velocity of GAT-1 mediated transport (Vmax) 
without a significant change in Km value, suggestive of an increase in the number 
of transporters at the membrane. This was directly confirmed by cell surface 
biotinylation and surface ELISA in astrocytes over-expressing wild type GAT-1 
or HA-tagged GAT-1, respectively. Constitutive recycling of neurotransmitter 
transporters is known to occur in neurons (Wang and Quick, 2005; Jiang and 
Chen, 2009). Therefore, and if this would apply to astrocytes, enhanced 
expression of GAT-1 on astrocytic surface membranes could result either from 
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inhibition of endocytosis or from enhancement of its recycling back to the 
membrane. The finding that monensin, which inhibits protein recycling back to 
the membrane without affecting endocytosis (Mollenhauer et al., 1990), does not 
prevent the effect of BDNF upon surface expression of GAT-1 molecules rules 
out an influence of BDNF upon membrane reinsertion of the transporters. 
Endocytosis frequently occurs through clathrin-dependent coated vesicle 
formation, a process that also depends on dynamin and, in neurons, controls 
synaptic vesicle turnover. Astrocytes, however, also possess a Ca2+-
dependent/dynamin independent endocytic pathway (Jiang and Chen, 2009), but 
since the dynamin inhibitor, dynasore, mimics the effect of BDNF and abrogates 
its influence upon surface expression of GAT-1, it seems likely that the effect of 
BDNF results from inhibition of GAT-1 internalization through a dynamin-
dependent process.  
BDNF has a complex pattern of modulation of GABAergic transmission, which is 
time-dependent and cell- and synapse-specific. In a time frame from minutes to a 
few hours, BDNF inhibits GABAA receptor mediated responses (Tanaka et al., 
1997) by downregulation of GABAA receptor surface expression (Brunig et al., 
2001). These fast BDNF actions are synapse specific, but the trend is towards a 
postsynaptic inhibition of GABAergic transmission, in particular towards an 
inhibition of inhibitory inputs to interneurons (Wardle and Poo, 2003). The 
inhibitory action of BDNF disappears after prolonged exposure to BDNF (Brunig 
et al., 2001), turning into a long-lasting facilitatory action of GABAA responses, 
associated with an increase in GABAA receptor clusters (Elmariah et al., 2005). 
These long-lasting effects of BDNF are more related to trophic than to fast 
signalling actions since they were shown to involve establishment of functional 
inhibitory synapses between interneurons (Elmariah et al., 2005). I now report 
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another fast and easily reversible mechanism operated by BDNF that influences 
GABAergic transmission. Thus, the enhanced GABA transport into astrocytes 
most probably contributes to transiently fasten the shut-down of GABAergic 
responses, a process that if added to the fast decrease in postsynaptic sensitivity to 
GABA (Tanaka et al., 1997; Brunig et al., 2001; Wardle and Poo, 2003) and to a 
facilitation of GABA transport into neurons (Law et al., 2000) will lead to a 
marked inhibition of inhibitory signalling. At the synaptic level this action of 
BDNF may, however, be slightly compensated by an inhibition of GAT-1 
mediated GABA uptake by the nerve endings (Vaz et al., 2008) as well as by an 
enhanced pre-synaptic release of GABA (Wardle and Poo, 2003). Therefore, the 
facilitatory action of BDNF upon GAT-1 might predominantly contribute to 
decrease tonic inhibition, that is to say, to a decreased exposure of extrasynaptic 
distant GABAA receptors (Lindquist and Birnir, 2006) to a persistently low 
concentration of ‘ambient’ GABA. It is also worthwhile to note that tonic 
inhibition is predominantly influenced by GAT-1, rather than GAT-3 (Kirmse et 
al., 2009) and that BDNF affected GAT-1, but not GAT-3 mediated transport in 
astrocytes. 
In accordance with previous reports (Rose et al., 2003; Bergami et al., 2008), the 
now reported action of BDNF in astrocytes might not involve TrkB-fl receptors 
since it was still evident when tyrosine kinase activity was blocked with K252a. 
Accordingly, no TrkB-fl or pTrkB immunoreactivity was detected in astrocytes, 
which were clearly immunopositive for the TrkB-t isoform. The TrkB-t receptor 
is characterized by lacking the tyrosine kinase domain, which is present in the full 
length TrkB receptor. Since it lacks the tyrosine kinase domain, the TrkB-t 
receptor does not directly activate the classical transduction pathways that 
characterize TrkB-fl receptor, namely the activation of ERK, PI3-K and PLC-γ 
pathway (Chao, 2003; Huang and Reichardt, 2003). TrkB-t isoforms can, 
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however, operate intracellular signalling pathway(s) leading to phosphorylation 
and changes in kinase activity (Baxter et al., 1997; Ohira et al., 2007). When 
testing which pathways activated by BDNF are related to its ability to modulate 
GAT-1, we found that the inhibition of PLC-, as well as the inhibition of MAP 
kinase pathways, prevented the BDNF action upon GAT-1 transporter, 
implicating these pathways in the action of the neurotrophin in the astrocytes. 
BDNF-induced activation of PLC-γ is often associated to PKC-δ activation 
(Patapoutian and Reichardt, 2001). Accordingly, blockade of PKC prevented the 
BDNF effect upon GAT-1 in astrocytes. An inhibitor of PI3-K did not prevent the 
effect of BDNF, suggesting the absence of involvement of PI3-K/Akt pathway on 
the action of BDNF upon GABA transport into astrocyes. Likewise, after a brief 
incubation with BDNF, there was an enhanced phosphorylation of PLC and of 
MAP kinase, but not of Akt. The signalling pathway operated by BDNF to quicky 
modulate GAT-1 in astrocytes is consistent with its time-frame of action, since 
PLC-γ/PKC-δ is associated with fast signalling, whereas the PI3-K/Akt pathway 
is mostly related to long lasting survival-related influences of BDNF (Blum and 
Konnerth, 2005). Nevertheless the blockade of tyrosine kinase by K252a 
diminished the Vmax of both GAT-1 and GAT-3 modulating GABA transporters in 
a similar way to what was already described in neurons for GAT-1 (Law et al., 
2000; Quick et al., 2004). 
Interestingly, astrocytes treated for a few minutes with BDNF had increased 
TrkB-t receptor levels in the cell membrane, suggesting a BDNF-induced 
translocation of TrkB-t receptor to the plasma membrane. At least in neurons, 
where membrane translocation of TrkB receptors has been mostly studied, acute 
exposure to BDNF rapidly (within seconds) increases TrkB surface expression, 
whereas long-lasting (within hours) treatment with BDNF leads to decreased 
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surface TrkB levels (Quick et al., 2004). A similar process might therefore occur 
in relation to surface expression of TrkB-t receptors in astrocytes. This process 
may result into a localized positive feed-back loop between neurons and 
astrocytes, where fast neuronal spiking leads to release of the neurotrophin, which 
can be taken up by astrocytes endowing these with the ability to resecrete it upon 
stimulation (Lindquist and Birnir, 2006), a mechanism that when coupled to a 
quick and BDNF-dependent overexpression of TrkB receptors at neuronal 
(Haapasalo et al., 2002) and astrocytic (present work) membranes further restricts 
neurotrophin actions to neuron–astrocyte contacts.  
Several studies demonstrated that the excitatory action of BDNF on synaptic 
transmission is fully dependent on adenosine A2A receptors activation, since it is 
absent when A2A receptors are blocked (Diógenes et al., 2004; Pousinha et al., 
2006; Diógenes et al., 2007; Fontinha et al., 2008), knocked-down (Tebano et al., 
2008) or upon removal of extracellular endogenous adenosine (Fontinha et al., 
2008; Assaife-Lopes et al., 2010). Activation of adenosine A2A receptors 
transactivate TrkB (Lee and Chao, 2001) and induce TrkB translocation to lipid 
rafts (Assaife-Lopes et al., 2010), which probably underlies the mechanisms 
behind the A2A/TrkB receptor facilitatory interaction. In the case of the inhibitory 
action of BDNF on presynaptic GAT-1 activity, it is modulated by A2A receptor 
activation but remains present either in the presence of A2A receptor antagonists or 
upon extracellular adenosine removal (Vaz et al., 2008). The now reported 
facilitatory action of BDNF upon GAT-1 in astrocytes was lost upon blockade of 
adenosine A2A receptors or extracellular adenosine removal. It therefore appears 
that fast excitatory actions of BDNF are those that require co-activation of 
adenosine A2A receptors by endogenously released adenosine. Interestingly, the 
present results allow to extend the adenosine/BDNF cross talk to astrocytes and to 
the truncated form of the TrkB receptor (TrkB-t). Noteworthy, the reported results 
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show for the first time a functional consequence of the crosstalk between TrkB-t 
and adenosine A2A receptors, indicating that the catalytic domain of the TrkB 
receptor is not involved in the cross-talk with A2A receptors.  
GABA has the ability to increase intracellular calcium levels in astrocytes and this 
action triggers the release of ATP from the astrocytes (Serrano et al., 2006). On 
the other hand, ATP is released with several neurotransmitters and triggers 
astrocytic calcium waves, leading to further release of ATP as well as of 
gliotransmitters  (Fields and Burnstock, 2006; Hamilton and Attwell, 2010). 
Released ATP can be extracellularly catabolised by a cascade of ectoenzymes 
leading to adenosine formation. Therefore, it is expected that the extracellular 
adenosine levels at the tripartite synapse are enough to activate high affinity 
adenosine receptors, namely A2A receptors, which will gate BDNF actions in 
astrocytes. BDNF itself is able to trigger calcium responses in astrocytes (Rose et 
al., 2003) therefore most probably further reinforcing the cycle of astrocyte-to-
neuron communication involving purines. In our experimental conditions, 
extracellular levels of adenosine were probably already high enough to maximally 
activate A2A receptors since further activation of these receptors with a selective 
A2A receptor agonist did not cause an enhancement of the facilitatory action of 
BDNF either upon GAT-1 mediated GABA transport or surface expression of 
GAT-1 transporters, or even upon surface expression of TrkB-t receptors.  
The present results allow to conclude that gating of TrkB-t receptors by A2A 
receptor activation is upstream of adenylate cyclase activation, since the effect of 
BDNF could be observed when A2A receptors were blocked but adenylate cyclase 
activated. Receptor tyrosine kinases (RTKs) and G-protein coupled receptors 
(GPCRs), by sharing protein signalling components specific for each receptor that 
are in close proximity, can form platforms, producing an integrate response upon 
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engagement of ligands (Pyne and Pyne, 2011). Examples of such platforms are 
lipid rafts, and A2A receptors are known to promote translocation of TrkB 
receptors to lipid rafts in a cyclic AMP-dependent manner (Assaife-Lopes et al., 
2010). Such proximity interaction may also occur with A2A receptors, adenylate 
cyclase and TrkB-t receptors in astrocytes, having an impact upon GAT-1 
mediated GABA transport.  
In conclusion, the data now reported highlight a new role for TrkB-t receptor in 
astrocytes, namely the modulation of activity and trafficking of GAT-1. This 
action of BDNF may impact upon synaptic transmission, namely decreasing tonic 
inhibition, and in such way adding to the plethora of mechanisms operated by the 
neurotrophin to reinforce synaptic activity. 
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6. GENERAL CONCLUSIONS 
Regulation of GABA transporters has been intensively studied for the last decades 
due to their ability to control neuronal excitability. Indeed GABA transporters are 
terapeutic targets for GABAergic regulation in patalogical conditions, such as 
epilepsy. 
The main conclusion of the work now described is that BDNF has opposite 
actions on GAT-1, depending on the location of the transporter, and this actions 
result from activation of different BDNF receptors by BDNF, namely TrkB-fl in 
nerve terminals and TrkB-t in astrocytes. 
Cell specific differences, not only related with different BDNF receptor subtypes, 
can also occur. There are previous reports showing differential modulation of 
GABA transporters according to the cell type. Lee and collaborators (2006) 
demonstrated that in patients with temporal lobe epilepsy there is an increase of 
GAT-3 expression in astrocytes and a decrease in GAT-1 expression in nerve 
terminals. Actually, it looks like there is a parallelism between results described 
by Lee and collaborators (2006) and the present results, since in nerve terminal, 
BDNF decreses GAT-1 mediated uptake while in astrocytes this neurotrophin 
enhances GABA transport (Figure 6.1.1A). The fact that BDNF modulates GAT-
1 but not GAT-3 is somehow puzzling, since GAT-1 and GAT-3 have very 
similar structure although with difference amino acid sequence. 
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Figure 6.1.1. Schematic representation of the influence of BDNF upon GAT-1 mediated GABA 
transport into nerve endings and astrocytes and modulation by A2A receptors. Modulation of 
GAT-1 transporter by BDNF in synaptosomes and astrocytes without activation of A2A receptors 
(A), with activation of A2A receptor (B) and blockade of A2A receptors (C).   
 
 
Thinking in the triparte synapse and in tonic and phasic inhibition, it is possible to 
speculate that the different BDNF effects on nerve terminals and astrocytes 
produce different responses at GABAergic transmission. GABA transporters 
located at synaptic level (nerve terminals) are mainly responsible for termination 
of phasic inhibition while transporters located at astrocytic level are mostly 
responsible for maintaing tonic inhibiton. Since BDNF decreses GABA uptake 
mediated by GAT-1 in nerve terminals, this may induce an increase of GABA at 
synaptic cleft leading to potentiation of GABergic transmission. On the other 
hand, since BDNF enhances GABA uptake in astrocytes there will be a decrease 
in GABA concentration in areas surrounding the synapse leading to a decrease in 
tonic inhibiton. This would imply not only that BDNF decreases the signal-to-
noise ratio of GABAergic transmission but also that this neurotrophin is favouring 
overall excitability    preserving the possibility of phasic inhibition. 
Another important finding obtained with this work is that the effect of BDNF on 
GAT-1 transporter in astrocytes occurs through activation of TrkB-t receptor, and 
not the TrkB-fl receptors. BDNF has different types of effect, depending on the 
isoform of TrkB receptor that is expressed in cells. TrkB-fl isoform has a tyrosine 
kinase domain which is responsible for activation of three pathways, the PLC, 
MAP kinase and PI3-K/Akt pathways while TrkB-t isoform lacks the tyrosine 
kinase domain, being the transduction pathways for this receptor not completely 
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clear. As I elucidated, the TrkB-t receptor somehow require coupling to the PLC-γ 
pathway affecting GAT-1 in astrocytes. 
Adenosine A2A receptor has been pointed out as modulator of the action of BDNF 
or its high-affinity receptors (for a review see Sebastião et al., 2010). In nerve 
terminals the effect of BDNF on GAT-1 was not modified by blockade of A2A 
receptors, indicating that this effect is not dependent upon activation of A2A 
receptor. Nevertheless the effect of BDNF was more pronounced when A2A 
receptors are activated (Figure 6.1.1B). In astrocytes, A2A receptor blockade fully 
prevented BDNF actions (Figure 6.1.1C). It is possible that the levels of 
endougenous adenosine are enough to tonically activate A2A receptors in 
astrocytes but not in synaptosomes. However, inspite of different endogenous 
levels of adenosine it is clear that A2A receptors activation is a necessary condition 
for the effect of BDNF upon GAT-1 in astrocytes but not in nerve ending. 
Interestingly, and since in astrocytes the effect of BDNF is exercised through 
TrkB-t it become evident that this TrkB isoform can also be modulated by A2AR; 
the mechanism behind this modulation requires further investigation.  
Altogether, the data reported in this thesis strongly suggest that BDNF modulates 
GABAergic transmission by modulating of GABA transporters located both at 
synapse and at astrocytes. Depending on the TrkB isoform that is activated, the 
BDNF effect will depend or not of A2A receptor co-activation. Thus it is likely 
that BDNF has different effects according to its site of action, which may have 
different but conserted consequences upon GABAergic transmission. The work I 
performed opens new aspects of BDNF research highlighting its ability to 
modulate the GABAergic system at the transporter level. 
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7. FUTURE PERSPECTIVES 
GAT-1 transporters located at nerve terminal, in addition to terminating synaptic 
transmission by clearing released transmitters from the extracelullar space, are the 
primary mechanism for replenishing transmitter stores and thus regulate 
presynaptic homeostasis. Thus the effect of BDNF on GAT-1 transporter in nerve 
terminals should be a target for further evaluation, of the functional consequences 
of this action of BDNF for the presynaptic GABAergic homeostasis.  
In nerve terminals I just analised one of the signalling pathways of TrkB-fl 
receptor, showing that the PLC pathway is the one that is mainly involved in fast 
effects of BDNF. Nevertheless MAP kinase and PI3-K/Akt pathways should also 
be studied since there are other rapid BDNF-mediated signalling cascades 
described that involve activation of MAP kinase and PI3-K/Akt (Johnson-Farley 
et al., 2006; Ortega et al., 2010).  
In nerve terminal, it is still unknown if the effect of BDNF changes Km or Vmax 
value, and if this is correlated with an increase of GAT-1 transport at synapse 
level. Law and collaboraters (2000) demonstrated that inhibition of tyrosine 
kinases decrease GABA uptake in culture neurons by decreasing Vmax and 
consequently by decreasing the number of functional transporters on plasma 
membrane. Therefore I could hypothesise that in synaptosomes BDNF diminished 
GABA uptake by decreasing the number of functional transporter on plasma 
membrane. To address this question biotinylation experiments (as in chapter 
4.2.4) are required.  Finally it would be of particular interest to evaluate how the 
effect of BDNF modulates tonic and/or phasic inhibition. Changes in the tonic vs 
phasic GABAA receptor-mediated transmission can be addressed by patch-clamp 
mode. Indeed, by measuring variations in the frequency and amplitude of 
spontaneous miniature inhibitory postsynaptic currents (IPSCs) one can evaluate 
effects upon phasic GABAergic transmission whilst changes in the holding 
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current upon fast application of GABAA antagonists will reflect tonic GABAA 
receptor-mediated currents.   
The discovery in the last decades that astrocytes are integral functional element of 
the synapse, responding to neuronal activity and regulating synaptic transmission 
and plasticity has changed the perception of brain functioning. The effect of 
BDNF on GAT-1 transporter obtained in astrocytes was opposite of the effect 
obtained in nerve terminals, and occured on both systems through activation of 
two different TrkB receptor isoforms. Until now what has been proposed is an 
interaction between TrkB-fl and A2A receptors, but the results obtained also 
demonstrated an interaction between TrkB-t and A2A receptors. My hypothesis 
concerning this issue is that the TrkB domain responsible for this interaction is the 
transmembrane domain since this portion of TrkB receptor is common to all 
isoforms of TrkB. Site directed mutagenesis approches can be used to test that 
hypothesis. 
In continuity with the present work I would like to evaluate if this modulatory 
effect of BDNF on GABA transport in astrocytes is correlated with the BDNF 
induced calcium wave observed also in astrocytes (Rose et al., 2003). On the 
other hand, it was also recently demonstrated that GABA induces an increase of 
intracellular calcium in astrocytes, which is correlated with a reduction of 
Na+/Ca2+ exchange, thereby leading to a Ca2+ increase sufficient to trigger Ca2+-
induced Ca2+ release via InsP3 receptors (Doengi et al., 2009). Is the increase of 
GABA uptake induced by BDNF sufficient to trigger a calcium wave? This is a 
question that could be addressed through quantification of the intracellular 
calcium rise in astrocytes. GAT-1 could be blocked and the consequences for a 
BDNF-induced calcium wave assessed. If modulation of GAT-1 is a requisite for 
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the BDNF-induced calcium signaling, the BDNF effect should be lost upon GAT-
1 blockade. 
Several questions remain unanswered concerning modulation of GABA 
transporters and all the functional roles that they will have at central nervous 
system under physiological or phatological conditions. With the work now 
presented I hope that science has taken one small step forward. 
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